{"gene":"LRIG1","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":1996,"finding":"LRIG1 (mouse LIG-1) was identified as a novel integral membrane glycoprotein containing 15 leucine-rich repeats, 3 immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail, with expression predominantly restricted to a subset of glial cells in the brain (Bergmann glia of cerebellum, olfactory bulb glia), suggesting a role as a cell-surface adhesion molecule or receptor.","method":"cDNA cloning, Northern blot, in situ hybridization, sequence analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — foundational structural characterization by multiple methods; single lab","pmids":["8798419"],"is_preprint":false},{"year":2001,"finding":"Human LIG1/LRIG1 was cloned and mapped to chromosome band 3p14.3 (a region frequently deleted in cancer); predicted to encode a transmembrane cell-surface protein homologous to Drosophila Kekkon-1, with highest expression in brain and lowest in spleen.","method":"cDNA cloning, chromosomal mapping, RT-PCR expression analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — direct cloning and chromosomal localization; single lab","pmids":["11414704"],"is_preprint":false},{"year":2002,"finding":"Targeted disruption of LIG-1/LRIG1 in mice causes psoriasiform epidermal hyperplasia, demonstrating that LRIG1 is required to restrain epidermal keratinocyte proliferation in vivo; LRIG1 is expressed in basal epidermal cells and outer root sheath cells.","method":"Gene targeting (knockout mouse), histology, in situ hybridization","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function with defined in vivo phenotype; replicated in subsequent studies","pmids":["12067728"],"is_preprint":false},{"year":2003,"finding":"LRIG1 protein migrates as two species (~143 kDa and ~134 kDa) under reducing conditions and can be cleaved into an N-terminal ~111 kDa fragment and a C-terminal ~32 kDa fragment; cell-surface biotinylation and confocal microscopy confirmed LRIG1 localizes to the plasma membrane.","method":"Immunoblotting, cell-surface biotinylation, confocal microscopy with LRIG1-GFP fusion protein","journal":"Cell and tissue research","confidence":"Medium","confidence_rationale":"Tier 2 — direct subcellular localization by multiple orthogonal methods; single lab","pmids":["12684867"],"is_preprint":false},{"year":2004,"finding":"LRIG1 transcript and protein are upregulated upon EGF stimulation; LRIG1 physically associates with all four ErbB/EGFR family members (EGFR/ErbB1, ErbB2, ErbB3, ErbB4); LRIG1 upregulation leads to enhanced ubiquitylation and degradation of EGFR by recruiting the E3 ubiquitin ligase c-Cbl, which simultaneously ubiquitylates both EGFR and LRIG1 and sorts them to degradation, establishing LRIG1 as a feedback negative attenuator of ErbB signaling.","method":"Co-immunoprecipitation, ubiquitylation assays, immunoblotting, EGF stimulation experiments","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal Co-IP, ubiquitylation assay, c-Cbl recruitment mechanism defined; replicated across multiple studies","pmids":["15282549"],"is_preprint":false},{"year":2004,"finding":"LRIG1 forms a complex with each ErbB receptor (EGFR, ErbB2, ErbB3, ErbB4) independent of growth factor binding in co-transfected cells; LRIG1 co-expression suppresses cellular EGFR levels, shortens receptor half-life, and enhances ligand-stimulated receptor ubiquitination, suppressing EGF-stimulated transformation of NIH3T3 fibroblasts and cell cycle progression in PC3 prostate tumor cells.","method":"Co-immunoprecipitation in 293T cells, receptor half-life assays, ubiquitination assays, soft agar transformation assay, cell cycle analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods across cell types; independently replicated","pmids":["15345710"],"is_preprint":false},{"year":2006,"finding":"A soluble ectodomain of LRIG1 containing only the leucine-rich repeat (LRR) domain inhibits ligand-independent and ligand-dependent EGFR activation and causes growth inhibition of EGFR-expressing carcinoma cells; high-affinity binding sites (Kd ~10 nM) for the LRIG1 ectodomain exist on EGFR-expressing cells, competitively displaced by EGF, indicating the LRR domain engages EGFR extracellularly.","method":"Cell growth inhibition assays, competitive binding assays, phosphorylation assays, ERK1/2 signaling assays with purified recombinant protein","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — purified recombinant protein with quantitative binding assay and functional rescue; multiple cell lines tested","pmids":["16847455"],"is_preprint":false},{"year":2006,"finding":"Lrig1 is a Myc target gene in mouse epidermis; loss of Lrig1 increases the proliferative capacity of epidermal stem cells in culture and causes epidermal hyperproliferation in vivo; Lrig1-expressing cells at the hair follicle junctional zone can give rise to all adult epidermal lineages (sebaceous gland, interfollicular epidermis) in skin reconstitution assays; siRNA knockdown in human keratinocytes increases cell-surface EGFR levels, enhances downstream pathway activation, and stimulates proliferation; Lrig1 also negatively regulates the Myc promoter.","method":"Single-cell expression profiling, siRNA knockdown, Lrig1 overexpression, flow cytometry, immunofluorescence, skin reconstitution assay, clonal growth analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America / Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function and gain-of-function with defined EGFR-pathway mechanism; replicated across two independent studies (PMID 16877544, 19427292)","pmids":["16877544","19427292"],"is_preprint":false},{"year":2006,"finding":"LRIG1 is a novel negative regulator of the Met receptor tyrosine kinase; LRIG1 interacts with Met independent of HGF stimulation and destabilizes Met in a Cbl-independent manner; LRIG1 overexpression reduces endogenous Met in breast cancer cells, impairs HGF responses, and opposes Met/ErbB2 synergy in driving cellular invasion; RNAi knockdown of LRIG1 increases Met receptor half-life.","method":"Co-immunoprecipitation, receptor half-life assays, siRNA knockdown, invasion assays, overexpression in breast cancer cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal gain/loss-of-function with mechanistic detail (Cbl-independence established); single lab but multiple orthogonal methods","pmids":["17178829"],"is_preprint":false},{"year":2008,"finding":"Lrig1 physically interacts with the Ret receptor tyrosine kinase and inhibits GDNF binding to Ret, prevents Ret recruitment to lipid rafts, blocks receptor autophosphorylation, and suppresses MAPK activation in response to GDNF; Lrig1 overexpression inhibits GDNF/Ret-induced neurite outgrowth cell-autonomously; Lrig1 siRNA knockdown potentiates neuronal differentiation and MAPK activation in response to GDNF.","method":"Co-immunoprecipitation, lipid raft fractionation, phosphorylation assays, siRNA knockdown, neurite outgrowth assays","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (Co-IP, lipid raft fractionation, gain/loss of function) demonstrating mechanism; single lab","pmids":["18171921"],"is_preprint":false},{"year":2008,"finding":"LRIG1 negatively regulates the oncogenic EGFRvIII mutant; EGFRvIII retains interaction with LRIG1 and is more sensitive to LRIG1 action than wild-type EGFR; LRIG1 regulation of EGFRvIII is distinct from Cbl-mediated degradation and alters EGFRvIII intracellular trafficking; LRIG1 RNAi silencing leads to enhanced EGFRvIII expression.","method":"Co-immunoprecipitation, siRNA knockdown, receptor trafficking assays, proliferation/survival/motility/invasion assays in glioblastoma cells","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — mechanistic distinction from Cbl pathway established by multiple assays; single lab","pmids":["18542056"],"is_preprint":false},{"year":2008,"finding":"LRIG1 protein levels are suppressed by ErbB receptor activation in breast tumor cells (but not in non-transformed breast epithelial cells), creating a feed-forward regulatory loop where aberrant ErbB2 signaling suppresses LRIG1, which in turn contributes to ErbB2 overexpression; RNAi-mediated LRIG1 knockdown further elevates ErbB2 and augments proliferation.","method":"siRNA knockdown, ectopic expression, immunoblotting, ErbB activation experiments in breast cancer cell lines and transgenic mouse tumors","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — gain/loss-of-function in cell lines and in vivo mouse tumors; single lab","pmids":["18922900"],"is_preprint":false},{"year":2010,"finding":"LRIG1 ectodomains are constitutively shed from the cell surface by metalloprotease activity (enhanced by ADAM17/TAPI-2-sensitive mechanism); shed LRIG1 ectodomains function in a paracrine manner to suppress EGF signaling in co-cultured cells without apparent downregulation of EGFR levels; shedding occurs in vivo as demonstrated by immunoblotting of tissue lysates.","method":"ADAM17 inhibitor treatment (TAPI-2), ADAM17 ectopic expression, co-culture assays, immunoblotting of conditioned media and tissue lysates","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — paracrine mechanism established by co-culture and inhibitor assays; single lab","pmids":["21087604"],"is_preprint":false},{"year":2012,"finding":"Lrig1 marks predominantly noncycling, long-lived intestinal stem cells at the crypt base; transcriptome profiling shows Lrig1+ colonic stem cells upregulate cell cycle repression and oxidative damage response genes; genetic ablation of Lrig1 results in heightened ErbB1-3 expression and duodenal adenomas; loss of Apc in Lrig1+ cells leads to intestinal adenomas, establishing Lrig1 as a pan-ErbB inhibitor, intestinal stem cell marker, and tumor suppressor in vivo.","method":"Lineage mapping (Cre-lox), transcriptome profiling (RNA-seq), genetic ablation (knockout mice), Apc conditional deletion","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic epistasis with defined ErbB signaling mechanism; highly cited, replicated","pmids":["22464327"],"is_preprint":false},{"year":2012,"finding":"Lrig1 controls the size of the intestinal stem cell niche by regulating the amplitude of ErbB growth factor signaling; Lrig1 is a negative-feedback regulator highly expressed in intestinal stem cells, and its loss expands the stem cell compartment; ErbB activation is established as a strong inductive signal for intestinal stem cell proliferation.","method":"Genetic loss-of-function (knockout mice), intestinal organoid culture, ErbB signaling assays","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic loss-of-function with defined ErbB pathway mechanism; independently confirmed by Powell et al.","pmids":["22388892"],"is_preprint":false},{"year":2012,"finding":"LRIG1 and LRIG3 functionally oppose one another: Lrig3 stabilizes ErbB receptors and opposes Lrig1 negative regulatory activity, while Lrig1 destabilizes Lrig3, identifying Lrig3 as a new target of Lrig1; this cross-talk regulates ErbB receptor levels.","method":"Co-immunoprecipitation, receptor stability assays, gain/loss-of-function overexpression experiments","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal functional opposition demonstrated by multiple assays; single lab","pmids":["23723069"],"is_preprint":false},{"year":2013,"finding":"LRIG1 forms a ternary complex with EGFR and E-cadherin to regulate contact inhibition; loss of Lrig1 is sufficient to promote murine airway hyperplasia through loss of contact inhibition; re-expression of LRIG1 in human lung cancer cells inhibits tumourigenesis; LRIG1 modulates EGFR activity downstream of E-cadherin-mediated cell-cell contact.","method":"Co-immunoprecipitation (ternary complex), Lrig1 knockout mouse (airway hyperplasia phenotype), re-expression in lung cancer cell lines, proliferation and tumourigenesis assays","journal":"The Journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 — ternary complex by Co-IP, in vivo genetic loss-of-function; single lab","pmids":["23208928"],"is_preprint":false},{"year":2013,"finding":"LRIG1 inhibits STAT3-dependent inflammatory signaling to maintain corneal homeostasis; Lrig1 deletion in mice results in impaired stem cell recruitment after injury and a cell-fate switch to keratinized skin-like epidermis leading to corneal blindness; inhibition of STAT3 in Lrig1-/- mice rescues pathological phenotypes; bone marrow chimera experiments show LRIG1 also coordinates bone marrow-derived inflammatory cell function.","method":"Knockout mouse (Lrig1-/-), STAT3 inhibition rescue experiments, transgenic STAT3 activation, bone marrow chimera experiments, wound repair assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic models (KO, transgenic, chimera) with defined STAT3 pathway mechanism","pmids":["24316976"],"is_preprint":false},{"year":2013,"finding":"LRIG1 modulates aggressiveness of head and neck cancers via the EGFR-MAPK-SPHK1 signaling pathway; inducible LRIG1 expression suppresses EGFR ligands/activators, MMPs, and SPHK1; LRIG1 also triggers integrin inactivation and reduces SNAI2, coupling EGFR signaling suppression to extracellular matrix remodeling.","method":"Inducible expression system, gene expression profiling, ChIP, western blotting, in vitro and in vivo tumor growth assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and expression profiling combined with functional assays; single lab","pmids":["23624915"],"is_preprint":false},{"year":2014,"finding":"USP8 is a LRIG1-specific deubiquitinating enzyme that interacts with LRIG1 and stabilizes it; the anti-Met antibody SAIT301 induces ubiquitination of LRIG1, promoting recruitment of Met/LRIG1 complex to the lysosome via Hrs interaction, leading to concomitant degradation of both LRIG1 and Met; USP8 inhibition reduces LRIG1 stability and impairs Met degradation.","method":"Co-immunoprecipitation, ubiquitination assays, lysosomal trafficking assays, siRNA knockdown of USP8","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — novel DUB identified by Co-IP and functional assays; single lab but multiple orthogonal approaches","pmids":["24828152"],"is_preprint":false},{"year":2014,"finding":"Anti-Met antibody SAIT301 mediates Cbl-independent Met degradation via LRIG1; LRIG1 enables Met downregulation without receptor activation, providing a mechanistic basis for non-agonistic Met-targeting therapy; LRIG1-mediated Met degradation is effective even in tumors with low/no Cbl expression or Met exon 14 deletion.","method":"Co-immunoprecipitation, receptor degradation assays, tumor xenograft models, Cbl-deficient cell lines","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — Cbl-independence mechanistically established in multiple tumor models; single lab","pmids":["23208509"],"is_preprint":false},{"year":2015,"finding":"LRIG1 is downregulated during epithelial-to-mesenchymal transition (EMT) of human mammary epithelial cells; LRIG1 depletion expands the stem cell population and accelerates EMT; LRIG1 expression in basal-B breast cancer cells provokes mesenchymal-to-epithelial transition, suppresses tumorsphere formation and invasive growth, and perturbs multiple RTK signaling pathways.","method":"siRNA knockdown, ectopic expression, 3D invasion assays, tumorsphere formation, EMT marker analysis, in vivo xenograft growth","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — gain/loss-of-function with in vivo validation; single lab","pmids":["26387542"],"is_preprint":false},{"year":2015,"finding":"LRIG1 regulates the postnatal development of interstitial cells of Cajal (ICC-DMP and ICC-SMP) from LRIG1-positive smooth muscle progenitors; Lrig1-null mice lose KIT, anoctamin-1, and neurokinin 1 receptor staining in DMP and SMP regions and exhibit significant delays in small intestinal transit.","method":"Lineage tracing (Lrig1-CreERT2 × Rosa26-LSL-YFP), immunofluorescence, intestinal transit assays in Lrig1-null mice","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — in vivo lineage tracing combined with functional transit assays in knockout mice; single lab","pmids":["25921371"],"is_preprint":false},{"year":2015,"finding":"The LRIG1 extracellular domain crystal structures were determined for the LRR domain and 3Ig domain at 2.3 Å resolution; the LRR domain and LRR-1Ig fragment are monomeric in solution while the 3Ig domain is dimeric; notably, no direct binding of isolated LRIG1 domains to soluble or cell-surface EGFR was detected by biosensor analysis, suggesting the full-length transmembrane context is required for receptor interaction.","method":"X-ray crystallography (2.3 Å), biosensor binding assays, baculovirus expression, analytical ultracentrifugation","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure determination combined with rigorous binding assays; important mechanistic constraint","pmids":["25765764"],"is_preprint":false},{"year":2015,"finding":"LRIG1 is an estrogen receptor α (ERα) target gene; estrogen stimulates LRIG1 accumulation, and disruption of estrogen induction enhances estrogen-dependent tumor cell growth; ErbB2 activation antagonizes ERα-driven LRIG1 expression; an LRIG1 mutant lacking the ErbB3 interaction motif cannot downregulate ErbB3, and LRIG1 loss in fulvestrant-treated cells permits ErbB3 upregulation and enhanced survival signaling.","method":"ChIP, ectopic expression, LRIG1 domain mutants, immunoblotting, ERα activation/inhibition experiments, cell growth assays","journal":"Oncogene / Molecular cancer research","confidence":"High","confidence_rationale":"Tier 2 — ERα-ChIP, domain mutant, and functional rescue across two independent studies","pmids":["26148232","21821674"],"is_preprint":false},{"year":2016,"finding":"Lrig1 physically interacts with TrkB and attenuates BDNF signaling; Lrig1 knockdown in hippocampal neurons enhances primary dendrite formation and proximal dendritic branching; Lrig1-deficient mice display morphological changes in proximal dendrite arborization and defects in social interaction; Lrig1 restricts BDNF-induced dendrite morphology in a cell-intrinsic manner.","method":"Co-immunoprecipitation (TrkB-Lrig1), siRNA knockdown, gain/loss-of-function in hippocampal neurons, Lrig1-/- mouse behavioral and morphological analysis","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 — Co-IP combined with in vivo KO mouse phenotype and gain/loss-of-function; single lab","pmids":["26935556"],"is_preprint":false},{"year":2018,"finding":"A yeast two-hybrid screen and BioPlex data mining identified a LRIG1 protein interaction network including RAB4A, PON2, GAL3ST1, ZBTB16, LRIG2, CNPY3, HLA-DRA, GML, CNPY4, LRRC40, LRIG3, GLRX3, and PTPRK as functionally relevant LRIG1 interactors; PON2 co-localizes with LRIG1 and functionally promotes LRIG1-mediated PDGFRα downregulation.","method":"Yeast two-hybrid screen, shRNA functional evaluation in triple co-transfection system, BioPlex data mining, co-localization imaging","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 — yeast two-hybrid with partial functional follow-up; single lab","pmids":["29317492"],"is_preprint":false},{"year":2019,"finding":"Androgen receptor (AR) directly transactivates LRIG1 through binding to AR-binding sites in the LRIG1 locus; LRIG1 dampens ERBB expression in a cell-type-dependent manner; LRIG1 exhibits tumor-suppressive functions in both AR+ and AR- prostate cancer xenograft models and inhibits ERBB2-driven tumor growth; transgenic LRIG1 inhibits tumor development in Hi-Myc and TRAMP mouse models.","method":"ChIP (AR binding to LRIG1 locus), xenograft models, transgenic mouse models (Hi-Myc, TRAMP), siRNA/ectopic expression, ERBB signaling analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — ChIP-validated direct AR transactivation combined with multiple in vivo genetic models","pmids":["31792211"],"is_preprint":false},{"year":2021,"finding":"LRIG1 is a gatekeeper of neural stem cell (NSC) exit from quiescence; BMP-4 signaling induces a dormant quiescent NSC state while combined BMP-4/FGF-2 signaling induces a primed quiescent state with high LRIG1 and CD9; genetic disruption of Lrig1 in SVZ NSCs leads to enhanced proliferation; mechanistically, LRIG1 enables EGFR protein levels to increase while limiting EGFR signaling activation, priming cells for cell cycle re-entry.","method":"Single-cell analysis, in vitro quiescence induction (BMP-4/FGF-2), Lrig1 conditional knockout in SVZ, EGFR signaling assays, engraftment into adult SVZ","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection of EGFR priming with in vivo genetic validation; single lab with multiple orthogonal approaches","pmids":["33972529"],"is_preprint":false},{"year":2021,"finding":"LRIG proteins (LRIG1 and LRIG3 but not LRIG2) regulate BMP signaling; Lrig-null mouse embryonic fibroblasts are deficient in adipogenesis and BMP signaling, and this defect is rescued by LRIG1 or LRIG3 ectopic expression; C. elegans sma-10/LRIG mutants exhibit a lipid storage defect, demonstrating evolutionary conservation of LRIG function in BMP/lipid metabolism.","method":"Lrig-null MEF adipogenesis assays, BMP signaling assays, ectopic expression rescue, C. elegans genetic analysis","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 — cross-species genetic validation of BMP pathway role; single lab","pmids":["33469151"],"is_preprint":false},{"year":2022,"finding":"Aberrant promoter CpG island methylation of LRIG1 is most prominent in basal/triple-negative breast cancer; global demethylation with 5-aza-2'-deoxycytidine restores LRIG1 expression; CRISPR/dCas9-mediated targeted TET1 demethylation and VP64 transcriptional activation at the LRIG1 CpG island increases LRIG1 expression and reduces cancer cell viability, demonstrating epigenetic silencing as a mechanism of LRIG1 repression.","method":"Methylation immunoprecipitation, 5-aza-2'-deoxycytidine treatment, CRISPR/dCas9-TET1 and dCas9-VP64 targeted demethylation/activation, qRT-PCR, immunoblotting","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — targeted epigenetic editing with functional consequence; single lab","pmids":["35440669"],"is_preprint":false},{"year":2024,"finding":"LRIG1 is a VISTA (V-domain immunoglobulin suppressor of T cell activation) binding partner that acts as an inhibitory immune checkpoint receptor on CD8+ T cells; T cell-specific LRIG1 deletion in mice leads to expansion of tumor-specific cytotoxic T lymphocytes with increased effector function, superior antitumor responses, and reduced quiescent CTL populations; LRIG1 suppresses T cell receptor signaling pathways upon VISTA engagement.","method":"VISTA-LRIG1 binding assays, T cell-specific conditional knockout mice, tumor challenge models, CTL functional assays, flow cytometry of T cell subsets","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 — receptor-ligand interaction combined with T cell-specific in vivo genetic model with defined signaling consequence","pmids":["38758807"],"is_preprint":false}],"current_model":"LRIG1 is a transmembrane leucine-rich repeat/immunoglobulin-domain protein that functions as a pan-negative regulator of multiple receptor tyrosine kinases (ErbB1-4, Met, Ret, TrkB, PDGFRα) by physically associating with receptors via its extracellular domain, recruiting c-Cbl to promote receptor ubiquitination and lysosomal degradation (with Met degradation proceeding via a Cbl-independent, USP8-regulated ubiquitination of LRIG1 itself), and by shedding its ectodomain (via ADAM17) to act in a paracrine fashion; LRIG1 also functions as an inhibitory immune checkpoint receptor on T cells by engaging VISTA to suppress TCR signaling, is transcriptionally regulated by EGF (feedback induction), estrogen receptor α, and androgen receptor, and is epigenetically silenced by promoter methylation in some cancers, while its loss-of-function in vivo causes epidermal hyperplasia, intestinal adenomas with elevated ErbB signaling, impaired neural stem cell quiescence, and loss of interstitial cells of Cajal."},"narrative":{"teleology":[{"year":1996,"claim":"Identification of LRIG1 (LIG-1) as a novel transmembrane glycoprotein with 15 LRRs and 3 Ig domains established its domain architecture and hinted at an adhesion/receptor function, but left its ligands and signaling role unknown.","evidence":"cDNA cloning, Northern blot, and in situ hybridization in mouse brain","pmids":["8798419"],"confidence":"Medium","gaps":["No ligand or binding partner identified","Expression survey limited to brain"]},{"year":2001,"claim":"Mapping human LRIG1 to chromosome 3p14.3—a region of frequent cancer deletion—raised the possibility of tumor-suppressive function but provided no mechanistic insight.","evidence":"cDNA cloning and chromosomal mapping of human LRIG1","pmids":["11414704"],"confidence":"Medium","gaps":["No functional data linking LRIG1 to tumor suppression","No protein-level characterization"]},{"year":2002,"claim":"Genetic ablation of Lrig1 in mice produced psoriasiform epidermal hyperplasia, demonstrating that LRIG1 is required to restrain keratinocyte proliferation in vivo and providing the first loss-of-function phenotype.","evidence":"Gene-targeted knockout mouse with histological analysis","pmids":["12067728"],"confidence":"High","gaps":["Molecular target of LRIG1 in epidermis not identified","Signaling pathway not defined"]},{"year":2004,"claim":"Discovery that LRIG1 physically associates with all four ErbB receptors, recruits c-Cbl to promote EGFR ubiquitination and degradation, and is itself transcriptionally induced by EGF established the core negative-feedback mechanism by which LRIG1 attenuates RTK signaling.","evidence":"Reciprocal Co-IP, ubiquitylation assays, receptor half-life measurements, and transformation assays in multiple cell types","pmids":["15282549","15345710"],"confidence":"High","gaps":["Whether c-Cbl recruitment is the universal mechanism for all RTK targets was untested","Structural basis of LRIG1–EGFR interaction unknown"]},{"year":2006,"claim":"Two advances broadened the LRIG1 model: the soluble LRR ectodomain was shown to bind EGFR with ~10 nM affinity and inhibit signaling extracellularly, while Lrig1 was identified as a Myc target marking junctional-zone epidermal stem cells capable of generating all epidermal lineages.","evidence":"Purified recombinant LRR domain binding/inhibition assays; single-cell profiling, skin reconstitution assays, and siRNA knockdown in keratinocytes","pmids":["16847455","16877544","19427292"],"confidence":"High","gaps":["Paracrine ectodomain shedding mechanism not yet characterized","Whether LRIG1 marks stem cells in other epithelia was unknown"]},{"year":2006,"claim":"LRIG1 was shown to negatively regulate Met receptor stability independently of c-Cbl, revealing that LRIG1 uses distinct degradation mechanisms for different RTK targets.","evidence":"Co-IP, receptor half-life assays, siRNA knockdown, and invasion assays in breast cancer cells","pmids":["17178829"],"confidence":"High","gaps":["Identity of the ubiquitin ligase or sorting machinery for Cbl-independent Met degradation was unknown","Whether Cbl-independence extends to other RTK targets untested"]},{"year":2008,"claim":"Extension of the pan-RTK inhibitor model: LRIG1 physically interacts with Ret, blocks GDNF binding and lipid-raft recruitment, and suppresses neurite outgrowth; separately, LRIG1 negatively regulates the oncogenic EGFRvIII mutant via a Cbl-independent trafficking mechanism.","evidence":"Co-IP, lipid raft fractionation, phosphorylation and neurite outgrowth assays (Ret); trafficking assays and siRNA in glioblastoma cells (EGFRvIII)","pmids":["18171921","18542056"],"confidence":"High","gaps":["Structural determinants of LRIG1 selectivity across different RTKs not defined","In vivo validation of Ret regulation not provided"]},{"year":2010,"claim":"Demonstration that ADAM17 cleaves LRIG1 to release a soluble ectodomain that suppresses EGF signaling in neighboring cells in a paracrine fashion established a non-cell-autonomous mode of action.","evidence":"ADAM17 inhibitor (TAPI-2), ADAM17 overexpression, co-culture paracrine assays, tissue lysate immunoblotting","pmids":["21087604"],"confidence":"Medium","gaps":["Cleavage site not mapped","In vivo relevance of paracrine signaling not established genetically","Mechanism of EGFR inhibition without receptor downregulation unclear"]},{"year":2012,"claim":"Lrig1 was established as a marker of quiescent intestinal stem cells and an in vivo tumor suppressor: Lrig1-null mice develop duodenal adenomas with elevated ErbB1-3, and Lrig1+ cells serve as the cell-of-origin for Apc-loss-driven adenomas, while separately LRIG3 was shown to functionally oppose LRIG1 by stabilizing ErbB receptors.","evidence":"Lineage tracing (Cre-lox), RNA-seq of Lrig1+ cells, Apc conditional deletion, intestinal organoid culture, receptor stability assays (LRIG3)","pmids":["22464327","22388892","23723069"],"confidence":"High","gaps":["Whether LRIG1/LRIG3 opposition operates stoichiometrically or through distinct receptor pools unclear","Mechanistic basis of LRIG1-mediated stem cell quiescence beyond ErbB inhibition not defined"]},{"year":2013,"claim":"LRIG1 was linked to contact inhibition via a ternary complex with EGFR and E-cadherin, and independently shown to inhibit STAT3-dependent inflammation in the cornea; Lrig1-null corneas undergo a fate switch to keratinized epidermis rescued by STAT3 inhibition.","evidence":"Co-IP of ternary complex, Lrig1 KO airway and corneal phenotypes, STAT3 inhibitor rescue, bone marrow chimera experiments","pmids":["23208928","24316976"],"confidence":"High","gaps":["Whether STAT3 regulation is direct or downstream of RTK inhibition not fully resolved","E-cadherin–LRIG1 interaction domain not mapped"]},{"year":2014,"claim":"Identification of USP8 as a LRIG1-specific deubiquitinase and elucidation of Cbl-independent Met degradation via LRIG1 ubiquitination and Hrs-mediated lysosomal sorting provided the missing machinery for the Cbl-independent degradation pathway.","evidence":"Co-IP, ubiquitination assays, lysosomal trafficking assays, USP8 siRNA knockdown","pmids":["24828152","23208509"],"confidence":"Medium","gaps":["Whether USP8 regulates LRIG1 stability for all RTK targets not tested","E3 ligase responsible for LRIG1 ubiquitination in the Cbl-independent pathway not identified"]},{"year":2015,"claim":"Crystal structures of the LRIG1 LRR and 3Ig domains revealed a monomeric LRR and dimeric 3Ig architecture, but no direct binding to soluble EGFR was detected, indicating that transmembrane context or coreceptors are required for receptor engagement; concurrently, LRIG1 was validated as a direct transcriptional target of ERα and AR, integrating hormonal regulation into the LRIG1 feedback circuit.","evidence":"X-ray crystallography at 2.3 Å, biosensor binding assays (EGFR); ChIP for ERα and AR binding, domain mutants, xenograft models","pmids":["25765764","26148232","21821674","31792211"],"confidence":"High","gaps":["Full-length LRIG1–EGFR complex structure not determined","Whether membrane anchoring or a coreceptor mediates the interaction is unknown"]},{"year":2015,"claim":"Lineage tracing demonstrated that Lrig1+ smooth muscle progenitors give rise to interstitial cells of Cajal (ICC), and Lrig1-null mice lose ICC markers and exhibit delayed intestinal transit, expanding LRIG1's physiological roles beyond epithelial homeostasis.","evidence":"Lrig1-CreERT2 lineage tracing, immunofluorescence for ICC markers, intestinal transit assays in knockout mice","pmids":["25921371"],"confidence":"High","gaps":["RTK target responsible for ICC phenotype not identified","Whether LRIG1 acts cell-autonomously in ICC progenitors not confirmed"]},{"year":2016,"claim":"LRIG1 was shown to physically associate with TrkB and restrict BDNF-driven dendrite morphogenesis; Lrig1-null mice display altered proximal dendritic arborization and social interaction deficits, adding neurotrophic receptor regulation to the pan-RTK inhibitor model.","evidence":"Co-IP of TrkB–LRIG1, siRNA and Lrig1 KO in hippocampal neurons, behavioral analysis","pmids":["26935556"],"confidence":"High","gaps":["Whether LRIG1 promotes TrkB degradation or only inhibits signaling not distinguished","Neural circuit basis of behavioral phenotype not mapped"]},{"year":2021,"claim":"LRIG1 was identified as a gatekeeper of neural stem cell exit from quiescence: BMP-4/FGF-2 primes quiescent NSCs by upregulating LRIG1, which allows EGFR accumulation while constraining its signaling, poising cells for re-entry; separately, LRIG1 and LRIG3 were shown to positively regulate BMP signaling and adipogenesis.","evidence":"Single-cell analysis, conditional Lrig1 KO in SVZ NSCs, BMP-4/FGF-2 quiescence assays; Lrig-null MEF adipogenesis rescue, C. elegans sma-10 genetics","pmids":["33972529","33469151"],"confidence":"High","gaps":["Mechanism by which LRIG1 allows EGFR accumulation without signaling is not molecularly resolved","BMP receptor interaction with LRIG1 not demonstrated by direct binding"]},{"year":2022,"claim":"Epigenetic silencing of LRIG1 via promoter CpG methylation was demonstrated in triple-negative breast cancer; CRISPR/dCas9-TET1 targeted demethylation restored LRIG1 expression and reduced cancer cell viability, providing a mechanistic explanation for LRIG1 loss in tumors lacking genetic deletion.","evidence":"Methylation immunoprecipitation, 5-aza-2′-deoxycytidine treatment, CRISPR/dCas9-TET1 and dCas9-VP64 epigenetic editing","pmids":["35440669"],"confidence":"Medium","gaps":["In vivo tumor suppression by demethylation not tested","Methylation status in other cancer types not systematically characterized in this study"]},{"year":2024,"claim":"A fundamentally new function was uncovered: LRIG1 is a receptor for the inhibitory ligand VISTA on CD8+ T cells; T cell-specific LRIG1 deletion expands tumor-specific cytotoxic T lymphocytes and enhances antitumor immunity, establishing LRIG1 as an immune checkpoint receptor beyond its RTK-regulatory roles.","evidence":"VISTA–LRIG1 binding assays, T cell-specific conditional knockout mice, tumor challenge models, CTL functional assays, flow cytometry","pmids":["38758807"],"confidence":"High","gaps":["Structural basis of VISTA–LRIG1 interaction not determined","Whether LRIG1 immune checkpoint function is independent of its RTK regulation not fully resolved","Therapeutic potential of LRIG1 blockade not tested in combination immunotherapy"]},{"year":null,"claim":"A full-length LRIG1–RTK complex structure explaining how transmembrane context enables receptor engagement (absent in isolated ectodomain), the identity of the E3 ligase for Cbl-independent RTK degradation, and the interplay between LRIG1's RTK-regulatory and immune checkpoint functions remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length LRIG1–EGFR or LRIG1–VISTA co-structure","E3 ligase for Cbl-independent pathway unknown","Relative contribution of RTK inhibition vs. VISTA engagement to LRIG1 tumor suppression in vivo not dissected"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,5,6,8,9,10,25,28]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[31]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,6,12]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[12]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,5,6,8,9,10,13,14,25,28,31]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,13,14,22]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[31]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,13,27,30]}],"complexes":[],"partners":["EGFR","ERBB2","ERBB3","ERBB4","MET","RET","NTRK2","USP8"],"other_free_text":[]},"mechanistic_narrative":"LRIG1 is a transmembrane negative-feedback regulator of receptor tyrosine kinase signaling that constrains stem cell proliferation, maintains epithelial homeostasis, and functions as an inhibitory immune checkpoint receptor. Its extracellular leucine-rich repeat and immunoglobulin-like domains physically associate with multiple RTKs—including all four ErbB family members, Met, Ret, and TrkB—and LRIG1 promotes their ubiquitination and degradation by recruiting c-Cbl (for EGFR) or through Cbl-independent, USP8-regulated ubiquitination of LRIG1 itself (for Met), while its ADAM17-shed ectodomain suppresses EGFR signaling in a paracrine fashion [PMID:15282549, PMID:17178829, PMID:21087604, PMID:24828152]. In vivo, LRIG1 loss causes epidermal hyperplasia, intestinal adenomas with elevated ErbB signaling, impaired neural stem cell quiescence, loss of interstitial cells of Cajal, and corneal degeneration driven by STAT3 hyperactivation [PMID:12067728, PMID:22464327, PMID:33972529, PMID:25921371, PMID:24316976]. LRIG1 also serves as a receptor for the inhibitory ligand VISTA on CD8+ T cells, where it suppresses TCR signaling and enforces cytotoxic T lymphocyte quiescence; T cell-specific LRIG1 deletion enhances antitumor immunity [PMID:38758807]."},"prefetch_data":{"uniprot":{"accession":"Q96JA1","full_name":"Leucine-rich repeats and immunoglobulin-like domains protein 1","aliases":[],"length_aa":1093,"mass_kda":119.1,"function":"Acts as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q96JA1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LRIG1","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":true,"resolved_as":"LIG1","ensg_id":"ENSG00000105486","cell_line_id":"CID000810","localizations":[{"compartment":"nuclear_punctae","grade":3},{"compartment":"nucleoplasm","grade":3}],"interactors":[{"gene":"UBE3B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000810","total_profiled":1310},"omim":[{"mim_id":"608870","title":"LEUCINE-RICH REPEATS- AND IMMUNOGLOBULIN-LIKE DOMAINS-CONTAINING PROTEIN 3; LRIG3","url":"https://www.omim.org/entry/608870"},{"mim_id":"608869","title":"LEUCINE-RICH REPEATS- AND IMMUNOGLOBULIN-LIKE DOMAINS-CONTAINING PROTEIN 2; LRIG2","url":"https://www.omim.org/entry/608869"},{"mim_id":"608868","title":"LEUCINE-RICH REPEATS- AND IMMUNOGLOBULIN-LIKE DOMAINS-CONTAINING PROTEIN 1; LRIG1","url":"https://www.omim.org/entry/608868"},{"mim_id":"605757","title":"PELOTA mRNA SURVEILLANCE AND RIBOSOME RESCUE FACTOR; PELO","url":"https://www.omim.org/entry/605757"},{"mim_id":"144700","title":"RENAL CELL CARCINOMA, NONPAPILLARY; RCC","url":"https://www.omim.org/entry/144700"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"pancreas","ntpm":136.0}],"url":"https://www.proteinatlas.org/search/LRIG1"},"hgnc":{"alias_symbol":["LIG-1","DKFZP586O1624","LIG1"],"prev_symbol":[]},"alphafold":{"accession":"Q96JA1","domains":[{"cath_id":"3.80.10.10","chopping":"320-491","consensus_level":"medium","plddt":93.783,"start":320,"end":491},{"cath_id":"2.60.40.10","chopping":"509-582","consensus_level":"high","plddt":87.1378,"start":509,"end":582},{"cath_id":"2.60.40.10","chopping":"605-690","consensus_level":"high","plddt":88.0147,"start":605,"end":690},{"cath_id":"2.60.40.10","chopping":"699-782","consensus_level":"high","plddt":90.7639,"start":699,"end":782}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96JA1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96JA1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96JA1-F1-predicted_aligned_error_v6.png","plddt_mean":74.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LRIG1","jax_strain_url":"https://www.jax.org/strain/search?query=LRIG1"},"sequence":{"accession":"Q96JA1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96JA1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96JA1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96JA1"}},"corpus_meta":[{"pmid":"22464327","id":"PMC_22464327","title":"The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22464327","citation_count":576,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19427292","id":"PMC_19427292","title":"Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermis.","date":"2009","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/19427292","citation_count":426,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22388892","id":"PMC_22388892","title":"Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling.","date":"2012","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22388892","citation_count":340,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16877544","id":"PMC_16877544","title":"Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16877544","citation_count":253,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15282549","id":"PMC_15282549","title":"LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation.","date":"2004","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15282549","citation_count":236,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15345710","id":"PMC_15345710","title":"The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15345710","citation_count":193,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11414704","id":"PMC_11414704","title":"Cloning, characterization, and expression of human LIG1.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11414704","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17178829","id":"PMC_17178829","title":"LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17178829","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12067728","id":"PMC_12067728","title":"Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia.","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12067728","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18171921","id":"PMC_18171921","title":"Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF.","date":"2008","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18171921","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18922900","id":"PMC_18922900","title":"Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18922900","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24052938","id":"PMC_24052938","title":"The interfollicular epidermis of adult mouse tail comprises two distinct cell lineages that are differentially regulated by Wnt, Edaradd, and Lrig1.","date":"2013","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24052938","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12234026","id":"PMC_12234026","title":"Is LRIG1 a tumour suppressor gene at chromosome 3p14.3?","date":"2002","source":"Acta oncologica (Stockholm, Sweden)","url":"https://pubmed.ncbi.nlm.nih.gov/12234026","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8798419","id":"PMC_8798419","title":"cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8798419","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23558895","id":"PMC_23558895","title":"LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.","date":"2013","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23558895","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33972529","id":"PMC_33972529","title":"LRIG1 is a gatekeeper to exit from quiescence in adult neural stem cells.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33972529","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14520461","id":"PMC_14520461","title":"LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT--PCR and immunohistochemical analysis.","date":"2003","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/14520461","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18542056","id":"PMC_18542056","title":"LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18542056","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16847455","id":"PMC_16847455","title":"A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16847455","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12684867","id":"PMC_12684867","title":"LRIG1 protein in human cells and tissues.","date":"2003","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/12684867","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24316976","id":"PMC_24316976","title":"LRIG1 inhibits STAT3-dependent inflammation to maintain corneal homeostasis.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24316976","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23723255","id":"PMC_23723255","title":"The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.","date":"2013","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23723255","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28814482","id":"PMC_28814482","title":"Lrig1+ gastric isthmal progenitor cells restore normal gastric lineage cells during damage recovery in adult mouse stomach.","date":"2017","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/28814482","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23624915","id":"PMC_23624915","title":"LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23624915","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24833705","id":"PMC_24833705","title":"Inducible loss of one Apc allele in Lrig1-expressing progenitor cells results in multiple distal colonic tumors with features of familial adenomatous polyposis.","date":"2014","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24833705","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30639225","id":"PMC_30639225","title":"Structure of the UHRF1 Tandem Tudor Domain Bound to a Methylated Non-histone Protein, LIG1, Reveals Rules for Binding and Regulation.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/30639225","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26935556","id":"PMC_26935556","title":"Lrig1 is a cell-intrinsic modulator of hippocampal dendrite complexity and BDNF signaling.","date":"2016","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/26935556","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38044421","id":"PMC_38044421","title":"hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma.","date":"2023","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38044421","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21781197","id":"PMC_21781197","title":"Arabidopsis ARP endonuclease functions in a branched base excision DNA repair pathway completed by LIG1.","date":"2011","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21781197","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19300910","id":"PMC_19300910","title":"Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.","date":"2009","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19300910","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38758807","id":"PMC_38758807","title":"LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses.","date":"2024","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38758807","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30081934","id":"PMC_30081934","title":"Isoliquiritigenin suppresses human melanoma growth by targeting miR-301b/LRIG1 signaling.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30081934","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21128282","id":"PMC_21128282","title":"LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer.","date":"2011","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21128282","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30181552","id":"PMC_30181552","title":"The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer.","date":"2018","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30181552","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23124613","id":"PMC_23124613","title":"Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.","date":"2012","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/23124613","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25860915","id":"PMC_25860915","title":"LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells.","date":"2015","source":"Cell stress & chaperones","url":"https://pubmed.ncbi.nlm.nih.gov/25860915","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23165628","id":"PMC_23165628","title":"Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma.","date":"2012","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23165628","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26387542","id":"PMC_26387542","title":"LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26387542","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23208928","id":"PMC_23208928","title":"LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development.","date":"2013","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23208928","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29391393","id":"PMC_29391393","title":"Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma.","date":"2018","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/29391393","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23665322","id":"PMC_23665322","title":"Gambogic acid induces EGFR degradation and Akt/mTORC1 inhibition through AMPK dependent-LRIG1 upregulation in cultured U87 glioma cells.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23665322","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23723069","id":"PMC_23723069","title":"Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23723069","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23850692","id":"PMC_23850692","title":"LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23850692","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22241084","id":"PMC_22241084","title":"LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22241084","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30320337","id":"PMC_30320337","title":"Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30320337","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29793318","id":"PMC_29793318","title":"Overexpressed miR-183 promoted glioblastoma radioresistance via down-regulating LRIG1.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29793318","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31792211","id":"PMC_31792211","title":"LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31792211","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24879564","id":"PMC_24879564","title":"Loss of LRIG1 locus increases risk of early and late relapse of stage I/II breast cancer.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24879564","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32174258","id":"PMC_32174258","title":"LncRNA MAGI2-AS3 inhibits the self-renewal of leukaemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia.","date":"2020","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/32174258","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17851870","id":"PMC_17851870","title":"LRIG1 expression in colorectal cancer.","date":"2007","source":"Acta oncologica (Stockholm, Sweden)","url":"https://pubmed.ncbi.nlm.nih.gov/17851870","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29317492","id":"PMC_29317492","title":"A protein interaction network centered on leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) regulates growth factor receptors.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29317492","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36539424","id":"PMC_36539424","title":"Mechanism of human Lig1 regulation by PCNA in Okazaki fragment sealing.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36539424","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24828152","id":"PMC_24828152","title":"USP8 modulates ubiquitination of LRIG1 for Met degradation.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24828152","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31488717","id":"PMC_31488717","title":"Targeted mobilization of Lrig1+ gastric epithelial stem cell populations by a carcinogenic Helicobacter pylori type IV secretion system.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31488717","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33476721","id":"PMC_33476721","title":"LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor.","date":"2021","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/33476721","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25960225","id":"PMC_25960225","title":"miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.","date":"2015","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/25960225","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33893245","id":"PMC_33893245","title":"microRNA-1246-containing extracellular vesicles from acute myeloid leukemia cells promote the survival of leukemia stem cells via the LRIG1-meditated STAT3 pathway.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33893245","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25921371","id":"PMC_25921371","title":"LRIG1 Regulates Ontogeny of Smooth Muscle-Derived Subsets of Interstitial Cells of Cajal in Mice.","date":"2015","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25921371","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16978290","id":"PMC_16978290","title":"LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87.","date":"2006","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/16978290","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28595997","id":"PMC_28595997","title":"HPV8 Field Cancerization in a Transgenic Mouse Model Is due to Lrig1+ Keratinocyte Stem Cell Expansion.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28595997","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30487162","id":"PMC_30487162","title":"LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial-mesenchymal transition.","date":"2019","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/30487162","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23337938","id":"PMC_23337938","title":"A role for LRIG1 in the regulation of malignant glioma aggressiveness.","date":"2013","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23337938","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25794708","id":"PMC_25794708","title":"Loss of Lrig1 leads to expansion of Brunner glands followed by duodenal adenomas with gastric metaplasia.","date":"2015","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25794708","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25801120","id":"PMC_25801120","title":"LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.","date":"2015","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/25801120","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28259645","id":"PMC_28259645","title":"Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy.","date":"2017","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28259645","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35790757","id":"PMC_35790757","title":"Structures of LIG1 that engage with mutagenic mismatches inserted by polβ in base excision repair.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35790757","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27010693","id":"PMC_27010693","title":"Association between Single-Nucleotide Polymorphisms of the hOGG1,NEIL1,APEX1, FEN1,LIG1, and LIG3 Genes and Alzheimer's Disease Risk.","date":"2016","source":"Neuropsychobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27010693","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29546323","id":"PMC_29546323","title":"Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.","date":"2018","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/29546323","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32183906","id":"PMC_32183906","title":"Lrig1 expression prospectively identifies stem cells in the ventricular-subventricular zone that are neurogenic throughout adult life.","date":"2020","source":"Neural development","url":"https://pubmed.ncbi.nlm.nih.gov/32183906","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35440669","id":"PMC_35440669","title":"Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35440669","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26097540","id":"PMC_26097540","title":"LRIG1 enhances the radiosensitivity of radioresistant human glioblastoma U251 cells via attenuation of the EGFR/Akt signaling pathway.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26097540","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33444456","id":"PMC_33444456","title":"LIG1 syndrome mutations remodel a cooperative network of ligand binding interactions to compromise ligation efficiency.","date":"2021","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/33444456","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22433838","id":"PMC_22433838","title":"Lrig1: a new master regulator of epithelial stem cells.","date":"2012","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/22433838","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24314030","id":"PMC_24314030","title":"Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity.","date":"2013","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/24314030","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26159916","id":"PMC_26159916","title":"LRIG1, a 3p tumor suppressor, represses EGFR signaling and is a novel epigenetic silenced gene in colorectal cancer.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26159916","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33053360","id":"PMC_33053360","title":"LRIG1-Mediated Inhibition of EGF Receptor Signaling Regulates Neural Precursor Cell Proliferation in the Neocortex.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33053360","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25460603","id":"PMC_25460603","title":"Using a new Lrig1 reporter mouse to assess differences between two Lrig1 antibodies in the intestine.","date":"2014","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/25460603","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28810655","id":"PMC_28810655","title":"MicroRNA-590-3p enhances the radioresistance in glioblastoma cells by targeting LRIG1.","date":"2017","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28810655","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28973660","id":"PMC_28973660","title":"From the Cover: High Susceptibility of Lrig1 Sebaceous Stem Cells to TCDD in Mice.","date":"2017","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/28973660","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26148232","id":"PMC_26148232","title":"Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26148232","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32149571","id":"PMC_32149571","title":"Evaluation of the influence of chronic low-dose radiation on DNA repair gene polymorphisms [XRCC1, XRCC3, PRKDC (XRCC7), LIG1, NEIL1] in individuals from normal and high level natural radiation areas of Kerala Coast.","date":"2020","source":"International journal of radiation biology","url":"https://pubmed.ncbi.nlm.nih.gov/32149571","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10447599","id":"PMC_10447599","title":"Phytochrome-induced expression of lig1, a homologue of the fission yeast cell-cycle checkpoint gene hus1, is associated with the developmental switch in Physarum polycephalum plasmodia.","date":"1999","source":"Current genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10447599","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33947959","id":"PMC_33947959","title":"LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33947959","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30248341","id":"PMC_30248341","title":"Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis.","date":"2018","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30248341","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25695283","id":"PMC_25695283","title":"Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/25695283","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25765764","id":"PMC_25765764","title":"LRIG1 extracellular domain: structure and function analysis.","date":"2015","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25765764","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38522520","id":"PMC_38522520","title":"Structures of LIG1 provide a mechanistic basis for understanding a lack of sugar discrimination against a ribonucleotide at the 3'-end of nick DNA.","date":"2024","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38522520","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24709893","id":"PMC_24709893","title":"LRIG1 as a potential novel marker for neoplastic transformation in ocular surface squamous neoplasia.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24709893","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38366780","id":"PMC_38366780","title":"Unfilled gaps by polβ lead to aberrant ligation by LIG1 at the downstream steps of base excision repair pathway.","date":"2024","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/38366780","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29745084","id":"PMC_29745084","title":"Resveratrol inhibits glioma cell growth via targeting LRIG1.","date":"2018","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29745084","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28099467","id":"PMC_28099467","title":"Senescent Atrophic Epidermis Retains Lrig1+ Stem Cells and Loses Wnt Signaling, a Phenotype Shared with CD44KO Mice.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28099467","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21567105","id":"PMC_21567105","title":"Suppression of bladder cancer cell tumorigenicity in an athymic mouse model by adenoviral vector-mediated transfer of LRIG1.","date":"2011","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21567105","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38454507","id":"PMC_38454507","title":"Dysregulation and antimetastatic function of circLRIG1 modulated by miR-214-3p/LRIG1 axis in bladder carcinoma.","date":"2024","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/38454507","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21431282","id":"PMC_21431282","title":"LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway.","date":"2011","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21431282","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23581227","id":"PMC_23581227","title":"LRIG1 enhances cisplatin sensitivity of glioma cell lines.","date":"2012","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/23581227","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36420140","id":"PMC_36420140","title":"Lrig1 regulates the balance between proliferation and quiescence in glioblastoma stem cells.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/36420140","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32316543","id":"PMC_32316543","title":"MicroRNA Expression Profiling of Normal and Malignant Human Colonic Stem Cells Identifies miRNA92a as a Regulator of the LRIG1 Stem Cell Gene.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32316543","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27352326","id":"PMC_27352326","title":"Association Between the LIG1 Polymorphisms and Lung Cancer Risk: A Meta-analysis of Case-Control Studies.","date":"2015","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/27352326","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24929328","id":"PMC_24929328","title":"Single-nucleotide polymorphisms of LIG1 associated with risk of lung cancer.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24929328","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17393120","id":"PMC_17393120","title":"Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line.","date":"2007","source":"Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban","url":"https://pubmed.ncbi.nlm.nih.gov/17393120","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21076409","id":"PMC_21076409","title":"Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21076409","citation_count":289,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22797727","id":"PMC_22797727","title":"Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22797727","citation_count":241,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21909108","id":"PMC_21909108","title":"Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21909108","citation_count":170,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32807901","id":"PMC_32807901","title":"UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination.","date":"2020","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32807901","citation_count":168,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20379614","id":"PMC_20379614","title":"Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.","date":"2010","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/20379614","citation_count":108,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33838681","id":"PMC_33838681","title":"NLRP7 deubiquitination by USP10 promotes tumor progression and tumor-associated macrophage polarization in colorectal cancer.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/33838681","citation_count":90,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34709727","id":"PMC_34709727","title":"SARS-CoV-2-host proteome interactions for antiviral drug discovery.","date":"2021","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/34709727","citation_count":86,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17624990","id":"PMC_17624990","title":"LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking.","date":"2007","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/17624990","citation_count":67,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23208509","id":"PMC_23208509","title":"Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23208509","citation_count":63,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21821674","id":"PMC_21821674","title":"Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer.","date":"2011","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/21821674","citation_count":58,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31073040","id":"PMC_31073040","title":"LMBR1L regulates lymphopoiesis through Wnt/β-catenin signaling.","date":"2019","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/31073040","citation_count":47,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24548859","id":"PMC_24548859","title":"Expression of LRIG1 is associated with good prognosis and human papillomavirus status in oropharyngeal cancer.","date":"2014","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24548859","citation_count":44,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21087604","id":"PMC_21087604","title":"Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1.","date":"2010","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21087604","citation_count":41,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24324551","id":"PMC_24324551","title":"Genome wide association study (GWAS) of Chagas cardiomyopathy in Trypanosoma cruzi seropositive subjects.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24324551","citation_count":41,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23648065","id":"PMC_23648065","title":"Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan.","date":"2013","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/23648065","citation_count":40,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23383273","id":"PMC_23383273","title":"VCP phosphorylation-dependent interaction partners prevent apoptosis in Helicobacter pylori-infected gastric epithelial cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23383273","citation_count":33,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34432599","id":"PMC_34432599","title":"C5orf51 is a component of the MON1-CCZ1 complex and controls RAB7A localization and stability during mitophagy.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/34432599","citation_count":33,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29450946","id":"PMC_29450946","title":"Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance.","date":"2018","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/29450946","citation_count":32,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34151794","id":"PMC_34151794","title":"Potential Novel Genes for Late-Onset Alzheimer's Disease in East-Asian Descent Identified by APOE-Stratified Genome-Wide Association Study.","date":"2021","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/34151794","citation_count":31,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25813475","id":"PMC_25813475","title":"LRIG1 is a prognostic biomarker in non-small cell lung cancer.","date":"2015","source":"Acta oncologica (Stockholm, Sweden)","url":"https://pubmed.ncbi.nlm.nih.gov/25813475","citation_count":28,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33469151","id":"PMC_33469151","title":"LRIG proteins regulate lipid metabolism via BMP signaling and affect the risk of type 2 diabetes.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/33469151","citation_count":26,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"36215168","id":"PMC_36215168","title":"TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing.","date":"2023","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36215168","citation_count":25,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18037903","id":"PMC_18037903","title":"Redistribution of LRIG proteins in psoriasis.","date":"2007","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/18037903","citation_count":22,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50998,"output_tokens":7371,"usd":0.131779},"stage2":{"model":"claude-opus-4-6","input_tokens":11055,"output_tokens":4639,"usd":0.256875},"total_usd":0.808716,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":65287,"output_tokens":8584,"usd":0.16231},"round2_rules_fired":"R2","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12272,"output_tokens":4419,"usd":0.257752}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"LRIG1 physically associates with all four ErbB/EGFR family receptors (EGFR, ErbB2, ErbB3, ErbB4) independent of growth factor binding, recruits the E3 ubiquitin ligase c-Cbl, and promotes ubiquitylation and lysosomal degradation of the receptors, thereby acting as a feedback negative regulator of ErbB signaling.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitylation assays, receptor degradation/half-life assays in co-transfected cells, EGF stimulation experiments\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal Co-IP, in vitro ubiquitylation assay, receptor half-life measurement; replicated independently in same year by Laederich et al.\",\n      \"pmids\": [\"15282549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"LRIG1 forms a complex with each ErbB receptor independently of ligand, suppresses cellular receptor levels, shortens receptor half-life, and enhances ligand-stimulated receptor ubiquitination, suppressing EGF-stimulated transformation and cell cycle progression.\",\n      \"method\": \"Co-transfection in 293T cells, Co-IP, receptor half-life assay, ubiquitination assay, NIH3T3 transformation assay, inducible expression in PC3 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Co-IP, half-life, ubiquitination, functional transformation assay), independent replication of EMBO Journal finding\",\n      \"pmids\": [\"15345710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LRIG1 is an EGF receptor antagonist in human epidermal stem cells; siRNA-mediated knockdown of LRIG1 increases cell-surface EGFR levels, enhances activation of downstream signaling pathways, and stimulates keratinocyte proliferation. LRIG1 also acts in part by negatively regulating the Myc promoter.\",\n      \"method\": \"siRNA knockdown, cell-surface EGFR measurement, single-cell expression profiling, clonal growth assays, overexpression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA KD with defined molecular and cellular phenotype, multiple orthogonal methods, replicated across labs\",\n      \"pmids\": [\"16877544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"A soluble ectodomain of LRIG1 containing only the leucine-rich repeats inhibits ligand-independent and ligand-dependent EGFR activation and causes growth inhibition specifically in EGFR-expressing carcinoma cells, binding to high-affinity sites (Kd=10 nM) competitively displaceable by EGF.\",\n      \"method\": \"Recombinant protein production, cell growth inhibition assays, binding affinity measurement, ERK1/2 phosphorylation assays, EGFR rescue experiments in EGFR-negative cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro binding assay with Kd determination, functional rescue experiment, multiple orthogonal methods\",\n      \"pmids\": [\"16847455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LRIG1 is a novel negative regulator of the Met receptor tyrosine kinase; it interacts with Met independent of HGF stimulation and destabilizes Met in a c-Cbl-independent manner, reducing Met half-life, impairing HGF responses, and opposing Met/ErbB2 synergy in driving cellular invasion.\",\n      \"method\": \"Co-immunoprecipitation, receptor half-life assay, siRNA knockdown, overexpression in breast cancer cells, invasion assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, receptor half-life, RNAi KD with defined phenotype, multiple orthogonal assays\",\n      \"pmids\": [\"17178829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Lrig1 physically interacts with the Ret receptor tyrosine kinase, inhibits GDNF binding to Ret, prevents Ret recruitment to lipid rafts, blocks receptor autophosphorylation, and attenuates MAPK activation and GDNF-induced neurite outgrowth in neuronal cells.\",\n      \"method\": \"Co-immunoprecipitation, lipid raft fractionation, receptor autophosphorylation assay, MAPK activation assay, siRNA knockdown, neurite outgrowth assay\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Co-IP, lipid raft fractionation, functional assays), gain and loss of function\",\n      \"pmids\": [\"18171921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"LRIG1 negatively regulates EGFRvIII, the constitutively active oncogenic EGFR mutant found in glioblastoma, through an interaction with EGFRvIII's extracellular domain that is distinct from Cbl-mediated regulation. LRIG1 knockdown alters EGFRvIII intracellular trafficking and elevates EGFRvIII expression.\",\n      \"method\": \"Co-immunoprecipitation, RNAi knockdown, receptor trafficking assays, overexpression, proliferation/survival/motility/invasion assays in glioblastoma cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP showing physical interaction, receptor trafficking assay, RNAi with defined phenotype, mechanistic dissection from Cbl pathway\",\n      \"pmids\": [\"18542056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In mouse epidermis, Lrig1 defines the hair follicle junctional zone stem cell population; loss of Lrig1 increases proliferative capacity in culture and causes epidermal hyperproliferation in vivo. Lrig1 is a Myc target gene, and loss of Lrig1 causes selective increase in beta-catenin-induced ectopic hair follicle formation.\",\n      \"method\": \"Lrig1 knockout mouse, lineage tracing, skin reconstitution assays, in vivo epidermal phenotyping\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with defined hyperproliferation phenotype and lineage tracing, multiple orthogonal assays\",\n      \"pmids\": [\"19427292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Lrig1 controls the size of the intestinal stem cell niche by negatively regulating ErbB signaling; Lrig1 loss in the intestine leads to heightened ErbB1-3 expression and duodenal adenomas, supporting ErbB negative regulation as a key mechanism for maintaining intestinal stem cell quiescence.\",\n      \"method\": \"Lrig1 knockout mouse, lineage mapping, transcriptome profiling of Lrig1+ colonic stem cells, genetic ablation of Apc in Lrig1+ cells\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO with defined ErbB upregulation and tumor phenotype, transcriptomics, epistasis with Apc\",\n      \"pmids\": [\"22464327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Lrig1 is a negative feedback regulator of ErbB signaling in intestinal stem cells; intestinal stem cell compartment size is regulated by ErbB signaling amplitude, and Lrig1 restricts this to maintain homeostasis.\",\n      \"method\": \"Lrig1 expression analysis in intestinal stem cells, intestinal stem cell niche size measurement in Lrig1 null mice, ErbB signaling readouts\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with defined cellular compartment phenotype, ErbB signaling measurements; independently replicates Cell paper findings\",\n      \"pmids\": [\"22388892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LRIG1 forms a ternary complex with EGFR and E-cadherin to regulate contact inhibition; deletion of Lrig1 is sufficient to promote airway hyperplasia through loss of contact inhibition, and re-expression of LRIG1 in human lung cancer cells inhibits tumorigenesis.\",\n      \"method\": \"Lrig1 deletion mouse model, ternary complex co-immunoprecipitation (LRIG1/EGFR/E-cadherin), re-expression in cancer cells, airway hyperplasia phenotyping\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP demonstrating ternary complex, KO mouse phenotype, functional rescue in human cancer cells\",\n      \"pmids\": [\"23208928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LRIG1 modulates EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling in head and neck cancer; LRIG1 suppresses expression of EGFR ligands/activators, MMPs and SPHK1, and triggers integrin inactivation with reduced SNAI2 expression.\",\n      \"method\": \"Inducible LRIG1 expression, gene expression profiling, chromatin immunoprecipitation, Western blot, shRNA knockdown, in vivo tumor growth assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP, gene expression profiling, in vivo), gain and loss of function\",\n      \"pmids\": [\"23624915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LRIG1 inhibits STAT3-dependent inflammation to maintain corneal homeostasis; deletion of Lrig1 impairs stem cell recruitment following injury, promotes cell-fate switch to keratinized epidermis leading to corneal blindness, and STAT3 inhibition rescues these phenotypes. Bone marrow chimera experiments showed LRIG1 also coordinates bone marrow-derived inflammatory cells.\",\n      \"method\": \"Lrig1 knockout mouse, constitutively active STAT3 transgenic mouse, pharmacological STAT3 inhibition, bone marrow chimera experiments, wound repair assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (STAT3 inhibition rescues Lrig1 KO phenotype), constitutively active STAT3 phenocopies, bone marrow chimeras; multiple orthogonal approaches\",\n      \"pmids\": [\"24316976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"USP8 is a LRIG1-specific deubiquitinating enzyme that interacts with LRIG1 and stabilizes it. Anti-Met antibody SAIT301 induces ubiquitination of LRIG1 by disrupting LRIG1-USP8 interaction, causing LRIG1 to recruit Met to lysosomes via interaction with Hrs, resulting in concomitant degradation of both LRIG1 and Met.\",\n      \"method\": \"Co-immunoprecipitation (LRIG1/USP8, LRIG1/Hrs), ubiquitination assays, lysosomal trafficking assays, antibody-induced degradation experiments\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifying USP8 as deubiquitinase, mechanistic pathway from ubiquitination to lysosomal degradation with Hrs interaction\",\n      \"pmids\": [\"24828152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Lrig1 and Lrig3 functionally oppose each other in regulation of ErbB receptors; Lrig3 opposes Lrig1 negative regulatory activity and stabilizes ErbB receptors, while Lrig1 destabilizes Lrig3, limiting Lrig3's positive effects on receptor levels.\",\n      \"method\": \"Co-transfection, receptor expression assays, functional opposition assays, cross-regulation experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional opposition demonstrated in cell lines, single lab\",\n      \"pmids\": [\"23723069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRIG1 expression is decreased during EMT of mammary epithelial cells; LRIG1 depletion expands the stem cell population and accelerates EMT, while LRIG1 expression in Basal B breast cancer cells provokes mesenchymal-to-epithelial transition, suppresses tumorsphere formation, and reduces invasive growth.\",\n      \"method\": \"siRNA knockdown, ectopic expression, mammosphere formation assay, 3D culture invasion assay, in vivo tumor growth, signaling pathway analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain and loss of function with defined cellular phenotypes, in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"26387542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRIG1 regulates the postnatal development of interstitial cells of Cajal (ICC-DMP and ICC-SMP) from smooth muscle progenitors; in Lrig1-null mice, loss of KIT staining in DMP and SMP regions and loss of ICC markers was observed, leading to significant delays in small intestinal transit.\",\n      \"method\": \"Lrig1-null mice, immunofluorescence, lineage tracing with Lrig1-CreERT2 and Myh11-CreERT2 crossed to Rosa26-YFP, intestinal transit assay\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — dual lineage tracing approach, KO mouse with defined cellular and functional phenotype\",\n      \"pmids\": [\"25921371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The crystal structure of the LRIG1 LRR domain and 3Ig domain were determined at 2.3 Å resolution; the LRR domain and LRR-1Ig fragment are monomers in solution, while the 3Ig domain is dimeric. Importantly, no direct binding of LRIG1 domains to EGFR was detected in solution or when EGFR was expressed on cell surfaces.\",\n      \"method\": \"X-ray crystallography (2.3 Å), biosensor binding analysis, baculovirus expression of recombinant LRIG1 domains\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure determination plus in vitro binding assay; single study but multiple rigorous methods\",\n      \"pmids\": [\"25765764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Lrig1 physically interacts with TrkB and attenuates BDNF signaling; loss of Lrig1 enhances primary dendrite formation and proximal dendritic branching of hippocampal neurons, phenocopying BDNF effects, while gain of Lrig1 restricts BDNF-induced dendrite morphology. Lrig1-deficient mice display defects in social interaction.\",\n      \"method\": \"Co-immunoprecipitation (Lrig1/TrkB), shRNA knockdown, gain and loss of function in hippocampal neurons, Lrig1 KO mouse behavioral assays, BDNF signaling measurements\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifying TrkB as binding partner, gain and loss of function with defined dendritic phenotype, in vivo behavioral validation\",\n      \"pmids\": [\"26935556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A protein interaction network centered on LRIG1 was identified; yeast two-hybrid screening and BioPlex data revealed novel LRIG1-interacting proteins including RAB4A, PON2, GAL3ST1, ZBTB16, LRIG2, CNPY3, LRIG3, GLRX3, PTPRK and others. PON2 co-localized with LRIG1 in transfected cells and functionally contributed to LRIG1-mediated downregulation of PDGFRα.\",\n      \"method\": \"Yeast two-hybrid screen, BioPlex data mining, triple co-transfection shRNA functional screen, co-localization by confocal microscopy\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — yeast two-hybrid plus functional shRNA screen, single lab, limited orthogonal validation for most interactors\",\n      \"pmids\": [\"29317492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Androgen receptor (AR) directly transactivates LRIG1 through binding to several AR-binding sites in the LRIG1 locus; LRIG1 dampens ERBB expression in a cell type-dependent manner and inhibits ERBB2-driven tumor growth. LRIG1 exhibits tumor-suppressive functions in both AR+ and AR- xenograft models.\",\n      \"method\": \"ChIP-seq (AR binding sites in LRIG1 locus), ectopic LRIG1 expression, transgenic mouse models (Hi-Myc, TRAMP), xenograft models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq identifying direct AR binding sites, multiple in vivo models validating tumor-suppressive function\",\n      \"pmids\": [\"31792211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LRIG1-mediated inhibition of EGFR signaling regulates neural precursor cell proliferation in the developing neocortex; constitutive or acute loss of Lrig1 causes neural stem cell expansion due to increased proliferation, and LRIG1 associates with and negatively regulates EGFR in cortical NSCs.\",\n      \"method\": \"Constitutive and conditional Lrig1 KO mice, co-immunoprecipitation (LRIG1/EGFR in NSCs), BrdU/EdU proliferation assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP in NSCs plus KO mouse phenotype, multiple orthogonal approaches\",\n      \"pmids\": [\"33053360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LRIG1 acts as a gatekeeper of neural stem cell (NSC) exit from quiescence; BMP-4 induces dormant quiescence, while BMP-4/FGF-2 combined induces a primed quiescent state with high LRIG1. Genetic disruption of Lrig1 in vivo within SVZ NSCs leads to enhanced proliferation. Mechanistically, LRIG1 enables EGFR protein levels to increase while limiting signaling activation to prime NSCs for cell cycle re-entry.\",\n      \"method\": \"In vitro NSC quiescence induction, Lrig1 conditional KO in SVZ, engraftment assays, EGFR level and signaling measurements, single-cell analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo conditional KO with defined proliferation phenotype, mechanistic dissection of EGFR levels vs. signaling, multiple orthogonal methods\",\n      \"pmids\": [\"33972529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LRIG1 loss in glioblastoma stem cells increases proliferation and reduces quiescence, impairs BMP signaling responses, and enhances tumor growth in vivo; overexpression of Lrig1 increases quiescence and impairs tumor formation. This implicates LRIG1 in controlling both EGFR and BMPR signaling in glioblastoma stem cells.\",\n      \"method\": \"Genetic ablation and overexpression of Lrig1 in mouse GBM stem cells, orthotopic transplantation, proliferation and quiescence markers, BMP signaling assays\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain and loss of function in GSCs with in vivo validation, single lab\",\n      \"pmids\": [\"36420140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LRIG1 CpG island promoter methylation silences LRIG1 expression in basal/triple-negative breast cancer; targeted TET1-mediated demethylation and VP64-mediated transcriptional activation using CRISPR/dCas9 restores LRIG1 expression and reduces cancer cell viability.\",\n      \"method\": \"Methylation immunoprecipitation, 5-aza-2'-deoxycytidine treatment, CRISPR/dCas9-TET1 and VP64 targeted demethylation/activation, qRT-PCR, immunoblotting, cell viability assay\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic epigenetic study with CRISPR-based functional validation demonstrating causal role of methylation in silencing\",\n      \"pmids\": [\"35440669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LRIG1 functions as an inhibitory immune checkpoint receptor that engages the immune checkpoint ligand VISTA; T cell-specific LRIG1 deletion leads to expansion of tumor-specific cytotoxic T lymphocytes with increased effector function, superior antitumor responses, and sustained tumor control.\",\n      \"method\": \"Co-immunoprecipitation (LRIG1/VISTA binding), T cell-specific Lrig1 conditional KO mouse, tumor challenge experiments, flow cytometry of T cell subsets, TCR signaling pathway analysis\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifying VISTA as binding partner, conditional KO with defined immune and antitumor phenotypes, multiple orthogonal methods\",\n      \"pmids\": [\"38758807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Targeted disruption of LIG-1/Lrig1 in mice results in psoriasiform epidermal hyperplasia; LIG-1 is expressed in basal cells of the epidermis and outer root sheath cells of hair follicles, and its loss correlates with enhanced proliferative capacity of epidermal keratinocytes.\",\n      \"method\": \"Gene targeting (KO mouse), histological analysis, in situ hybridization\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with defined hyperproliferative phenotype, expression characterization\",\n      \"pmids\": [\"12067728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"LIG-1 (LRIG1) was identified as a novel integral membrane glycoprotein with extracellular leucine-rich repeats, immunoglobulin-like domains, a transmembrane region, and cytoplasmic tail; Northern blot and in situ hybridization showed predominant expression in glial cells (Bergmann glia of cerebellum, olfactory bulb glial cells) in mouse brain.\",\n      \"method\": \"cDNA cloning, sequence analysis, Northern blot, in situ hybridization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — original cloning/characterization paper, structural domain determination confirmed by sequence analysis and expression mapping\",\n      \"pmids\": [\"8798419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"LRIG1 protein localizes to the cell surface in multiple cell types; it migrates as 143 kDa and 134 kDa species, and may be cleaved into 111 kDa N-terminal and 32 kDa C-terminal fragments. Cell-surface biotinylation and confocal microscopy confirmed plasma membrane localization.\",\n      \"method\": \"Cell-surface biotinylation, confocal microscopy of LRIG1-GFP fusion, Western blot, immunohistochemistry, denaturing PAGE\",\n      \"journal\": \"Cell and tissue research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct localization by biotinylation and confocal microscopy, biochemical characterization of cleavage\",\n      \"pmids\": [\"12684867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation; estrogen-dependent LRIG1 expression maintains low ErbB3, and an LRIG1 mutant lacking the ErbB3 interaction motif was insufficient to downregulate ErbB3, demonstrating that the ErbB3 interaction domain of LRIG1 is required for ErbB3 regulation.\",\n      \"method\": \"Domain deletion mutagenesis of LRIG1 (ErbB3 interaction motif deletion), ectopic expression from estrogen-independent promoter, ErbB3 level measurement, fulvestrant treatment, growth inhibition assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis identifying critical interaction domain, mechanistic linkage of estrogen-LRIG1-ErbB3 axis\",\n      \"pmids\": [\"26148232\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LRIG1 is a transmembrane leucine-rich repeat and immunoglobulin-domain-containing protein that functions as a pan-negative regulator of multiple receptor tyrosine kinases (EGFR/ErbB family, Met, Ret, TrkB, PDGFRα, IGF-1R) by physically associating with their extracellular domains, recruiting c-Cbl E3 ubiquitin ligase to promote receptor ubiquitylation and lysosomal degradation, while also being itself regulated by the deubiquitinase USP8; additionally, LRIG1 engages the immune checkpoint ligand VISTA on T cells to suppress antitumor immunity, forms a ternary complex with EGFR and E-cadherin to enforce contact inhibition, interacts with TrkB to restrict BDNF-mediated dendritic branching, and maintains stem cell quiescence in multiple tissues by calibrating ErbB/EGFR signaling amplitude, with its expression regulated by androgen receptor transcriptional activation and epigenetically silenced by promoter CpG methylation in cancer.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nLooking at the corpus, I need to classify papers:\n\n**EXCLUDE (alias collisions or alt-locus products):**\n- Papers [26], [28], [29] (corpus), [52], [66], [72], [87], [89] - these describe DNA Ligase I (LIG1), not LRIG1\n- Papers [29], [34] (additional) - DNA Ligase I papers\n- Paper [82] - Physarum polycephalum lig1 (symbol collision, incompatible organism/function)\n- Papers [93] - circLRIG1 (alt-locus circRNA product) - EXCLUDE as alt-locus product\n- Papers about UHRF1/LIG1 methylation [26 corpus], Arabidopsis LIG1 [29 corpus], SRSF1/LIG1 [34 corpus], PCNA/Lig1 [52 corpus], LIG1 syndrome [72 corpus], LIG1 structures [66, 87 corpus], LIG1 BER [89 corpus]\n- GWAS/association papers about DNA LIG1 [67, 81, 98, 99 corpus]\n\nAll remaining papers describe LRIG1 (leucine-rich repeats and immunoglobulin-like domains 1), the canonical transmembrane protein. Now I extract mechanistic discoveries.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"LRIG1 (mouse LIG-1) was identified as a novel integral membrane glycoprotein containing 15 leucine-rich repeats, 3 immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail, with expression predominantly restricted to a subset of glial cells in the brain (Bergmann glia of cerebellum, olfactory bulb glia), suggesting a role as a cell-surface adhesion molecule or receptor.\",\n      \"method\": \"cDNA cloning, Northern blot, in situ hybridization, sequence analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — foundational structural characterization by multiple methods; single lab\",\n      \"pmids\": [\"8798419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Human LIG1/LRIG1 was cloned and mapped to chromosome band 3p14.3 (a region frequently deleted in cancer); predicted to encode a transmembrane cell-surface protein homologous to Drosophila Kekkon-1, with highest expression in brain and lowest in spleen.\",\n      \"method\": \"cDNA cloning, chromosomal mapping, RT-PCR expression analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct cloning and chromosomal localization; single lab\",\n      \"pmids\": [\"11414704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Targeted disruption of LIG-1/LRIG1 in mice causes psoriasiform epidermal hyperplasia, demonstrating that LRIG1 is required to restrain epidermal keratinocyte proliferation in vivo; LRIG1 is expressed in basal epidermal cells and outer root sheath cells.\",\n      \"method\": \"Gene targeting (knockout mouse), histology, in situ hybridization\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with defined in vivo phenotype; replicated in subsequent studies\",\n      \"pmids\": [\"12067728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"LRIG1 protein migrates as two species (~143 kDa and ~134 kDa) under reducing conditions and can be cleaved into an N-terminal ~111 kDa fragment and a C-terminal ~32 kDa fragment; cell-surface biotinylation and confocal microscopy confirmed LRIG1 localizes to the plasma membrane.\",\n      \"method\": \"Immunoblotting, cell-surface biotinylation, confocal microscopy with LRIG1-GFP fusion protein\",\n      \"journal\": \"Cell and tissue research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular localization by multiple orthogonal methods; single lab\",\n      \"pmids\": [\"12684867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"LRIG1 transcript and protein are upregulated upon EGF stimulation; LRIG1 physically associates with all four ErbB/EGFR family members (EGFR/ErbB1, ErbB2, ErbB3, ErbB4); LRIG1 upregulation leads to enhanced ubiquitylation and degradation of EGFR by recruiting the E3 ubiquitin ligase c-Cbl, which simultaneously ubiquitylates both EGFR and LRIG1 and sorts them to degradation, establishing LRIG1 as a feedback negative attenuator of ErbB signaling.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitylation assays, immunoblotting, EGF stimulation experiments\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal Co-IP, ubiquitylation assay, c-Cbl recruitment mechanism defined; replicated across multiple studies\",\n      \"pmids\": [\"15282549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"LRIG1 forms a complex with each ErbB receptor (EGFR, ErbB2, ErbB3, ErbB4) independent of growth factor binding in co-transfected cells; LRIG1 co-expression suppresses cellular EGFR levels, shortens receptor half-life, and enhances ligand-stimulated receptor ubiquitination, suppressing EGF-stimulated transformation of NIH3T3 fibroblasts and cell cycle progression in PC3 prostate tumor cells.\",\n      \"method\": \"Co-immunoprecipitation in 293T cells, receptor half-life assays, ubiquitination assays, soft agar transformation assay, cell cycle analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods across cell types; independently replicated\",\n      \"pmids\": [\"15345710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"A soluble ectodomain of LRIG1 containing only the leucine-rich repeat (LRR) domain inhibits ligand-independent and ligand-dependent EGFR activation and causes growth inhibition of EGFR-expressing carcinoma cells; high-affinity binding sites (Kd ~10 nM) for the LRIG1 ectodomain exist on EGFR-expressing cells, competitively displaced by EGF, indicating the LRR domain engages EGFR extracellularly.\",\n      \"method\": \"Cell growth inhibition assays, competitive binding assays, phosphorylation assays, ERK1/2 signaling assays with purified recombinant protein\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — purified recombinant protein with quantitative binding assay and functional rescue; multiple cell lines tested\",\n      \"pmids\": [\"16847455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Lrig1 is a Myc target gene in mouse epidermis; loss of Lrig1 increases the proliferative capacity of epidermal stem cells in culture and causes epidermal hyperproliferation in vivo; Lrig1-expressing cells at the hair follicle junctional zone can give rise to all adult epidermal lineages (sebaceous gland, interfollicular epidermis) in skin reconstitution assays; siRNA knockdown in human keratinocytes increases cell-surface EGFR levels, enhances downstream pathway activation, and stimulates proliferation; Lrig1 also negatively regulates the Myc promoter.\",\n      \"method\": \"Single-cell expression profiling, siRNA knockdown, Lrig1 overexpression, flow cytometry, immunofluorescence, skin reconstitution assay, clonal growth analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America / Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function and gain-of-function with defined EGFR-pathway mechanism; replicated across two independent studies (PMID 16877544, 19427292)\",\n      \"pmids\": [\"16877544\", \"19427292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LRIG1 is a novel negative regulator of the Met receptor tyrosine kinase; LRIG1 interacts with Met independent of HGF stimulation and destabilizes Met in a Cbl-independent manner; LRIG1 overexpression reduces endogenous Met in breast cancer cells, impairs HGF responses, and opposes Met/ErbB2 synergy in driving cellular invasion; RNAi knockdown of LRIG1 increases Met receptor half-life.\",\n      \"method\": \"Co-immunoprecipitation, receptor half-life assays, siRNA knockdown, invasion assays, overexpression in breast cancer cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function with mechanistic detail (Cbl-independence established); single lab but multiple orthogonal methods\",\n      \"pmids\": [\"17178829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Lrig1 physically interacts with the Ret receptor tyrosine kinase and inhibits GDNF binding to Ret, prevents Ret recruitment to lipid rafts, blocks receptor autophosphorylation, and suppresses MAPK activation in response to GDNF; Lrig1 overexpression inhibits GDNF/Ret-induced neurite outgrowth cell-autonomously; Lrig1 siRNA knockdown potentiates neuronal differentiation and MAPK activation in response to GDNF.\",\n      \"method\": \"Co-immunoprecipitation, lipid raft fractionation, phosphorylation assays, siRNA knockdown, neurite outgrowth assays\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Co-IP, lipid raft fractionation, gain/loss of function) demonstrating mechanism; single lab\",\n      \"pmids\": [\"18171921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"LRIG1 negatively regulates the oncogenic EGFRvIII mutant; EGFRvIII retains interaction with LRIG1 and is more sensitive to LRIG1 action than wild-type EGFR; LRIG1 regulation of EGFRvIII is distinct from Cbl-mediated degradation and alters EGFRvIII intracellular trafficking; LRIG1 RNAi silencing leads to enhanced EGFRvIII expression.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, receptor trafficking assays, proliferation/survival/motility/invasion assays in glioblastoma cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic distinction from Cbl pathway established by multiple assays; single lab\",\n      \"pmids\": [\"18542056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"LRIG1 protein levels are suppressed by ErbB receptor activation in breast tumor cells (but not in non-transformed breast epithelial cells), creating a feed-forward regulatory loop where aberrant ErbB2 signaling suppresses LRIG1, which in turn contributes to ErbB2 overexpression; RNAi-mediated LRIG1 knockdown further elevates ErbB2 and augments proliferation.\",\n      \"method\": \"siRNA knockdown, ectopic expression, immunoblotting, ErbB activation experiments in breast cancer cell lines and transgenic mouse tumors\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain/loss-of-function in cell lines and in vivo mouse tumors; single lab\",\n      \"pmids\": [\"18922900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LRIG1 ectodomains are constitutively shed from the cell surface by metalloprotease activity (enhanced by ADAM17/TAPI-2-sensitive mechanism); shed LRIG1 ectodomains function in a paracrine manner to suppress EGF signaling in co-cultured cells without apparent downregulation of EGFR levels; shedding occurs in vivo as demonstrated by immunoblotting of tissue lysates.\",\n      \"method\": \"ADAM17 inhibitor treatment (TAPI-2), ADAM17 ectopic expression, co-culture assays, immunoblotting of conditioned media and tissue lysates\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — paracrine mechanism established by co-culture and inhibitor assays; single lab\",\n      \"pmids\": [\"21087604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Lrig1 marks predominantly noncycling, long-lived intestinal stem cells at the crypt base; transcriptome profiling shows Lrig1+ colonic stem cells upregulate cell cycle repression and oxidative damage response genes; genetic ablation of Lrig1 results in heightened ErbB1-3 expression and duodenal adenomas; loss of Apc in Lrig1+ cells leads to intestinal adenomas, establishing Lrig1 as a pan-ErbB inhibitor, intestinal stem cell marker, and tumor suppressor in vivo.\",\n      \"method\": \"Lineage mapping (Cre-lox), transcriptome profiling (RNA-seq), genetic ablation (knockout mice), Apc conditional deletion\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic epistasis with defined ErbB signaling mechanism; highly cited, replicated\",\n      \"pmids\": [\"22464327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Lrig1 controls the size of the intestinal stem cell niche by regulating the amplitude of ErbB growth factor signaling; Lrig1 is a negative-feedback regulator highly expressed in intestinal stem cells, and its loss expands the stem cell compartment; ErbB activation is established as a strong inductive signal for intestinal stem cell proliferation.\",\n      \"method\": \"Genetic loss-of-function (knockout mice), intestinal organoid culture, ErbB signaling assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic loss-of-function with defined ErbB pathway mechanism; independently confirmed by Powell et al.\",\n      \"pmids\": [\"22388892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LRIG1 and LRIG3 functionally oppose one another: Lrig3 stabilizes ErbB receptors and opposes Lrig1 negative regulatory activity, while Lrig1 destabilizes Lrig3, identifying Lrig3 as a new target of Lrig1; this cross-talk regulates ErbB receptor levels.\",\n      \"method\": \"Co-immunoprecipitation, receptor stability assays, gain/loss-of-function overexpression experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal functional opposition demonstrated by multiple assays; single lab\",\n      \"pmids\": [\"23723069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LRIG1 forms a ternary complex with EGFR and E-cadherin to regulate contact inhibition; loss of Lrig1 is sufficient to promote murine airway hyperplasia through loss of contact inhibition; re-expression of LRIG1 in human lung cancer cells inhibits tumourigenesis; LRIG1 modulates EGFR activity downstream of E-cadherin-mediated cell-cell contact.\",\n      \"method\": \"Co-immunoprecipitation (ternary complex), Lrig1 knockout mouse (airway hyperplasia phenotype), re-expression in lung cancer cell lines, proliferation and tumourigenesis assays\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ternary complex by Co-IP, in vivo genetic loss-of-function; single lab\",\n      \"pmids\": [\"23208928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LRIG1 inhibits STAT3-dependent inflammatory signaling to maintain corneal homeostasis; Lrig1 deletion in mice results in impaired stem cell recruitment after injury and a cell-fate switch to keratinized skin-like epidermis leading to corneal blindness; inhibition of STAT3 in Lrig1-/- mice rescues pathological phenotypes; bone marrow chimera experiments show LRIG1 also coordinates bone marrow-derived inflammatory cell function.\",\n      \"method\": \"Knockout mouse (Lrig1-/-), STAT3 inhibition rescue experiments, transgenic STAT3 activation, bone marrow chimera experiments, wound repair assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models (KO, transgenic, chimera) with defined STAT3 pathway mechanism\",\n      \"pmids\": [\"24316976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LRIG1 modulates aggressiveness of head and neck cancers via the EGFR-MAPK-SPHK1 signaling pathway; inducible LRIG1 expression suppresses EGFR ligands/activators, MMPs, and SPHK1; LRIG1 also triggers integrin inactivation and reduces SNAI2, coupling EGFR signaling suppression to extracellular matrix remodeling.\",\n      \"method\": \"Inducible expression system, gene expression profiling, ChIP, western blotting, in vitro and in vivo tumor growth assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and expression profiling combined with functional assays; single lab\",\n      \"pmids\": [\"23624915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"USP8 is a LRIG1-specific deubiquitinating enzyme that interacts with LRIG1 and stabilizes it; the anti-Met antibody SAIT301 induces ubiquitination of LRIG1, promoting recruitment of Met/LRIG1 complex to the lysosome via Hrs interaction, leading to concomitant degradation of both LRIG1 and Met; USP8 inhibition reduces LRIG1 stability and impairs Met degradation.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, lysosomal trafficking assays, siRNA knockdown of USP8\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel DUB identified by Co-IP and functional assays; single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"24828152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Anti-Met antibody SAIT301 mediates Cbl-independent Met degradation via LRIG1; LRIG1 enables Met downregulation without receptor activation, providing a mechanistic basis for non-agonistic Met-targeting therapy; LRIG1-mediated Met degradation is effective even in tumors with low/no Cbl expression or Met exon 14 deletion.\",\n      \"method\": \"Co-immunoprecipitation, receptor degradation assays, tumor xenograft models, Cbl-deficient cell lines\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Cbl-independence mechanistically established in multiple tumor models; single lab\",\n      \"pmids\": [\"23208509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRIG1 is downregulated during epithelial-to-mesenchymal transition (EMT) of human mammary epithelial cells; LRIG1 depletion expands the stem cell population and accelerates EMT; LRIG1 expression in basal-B breast cancer cells provokes mesenchymal-to-epithelial transition, suppresses tumorsphere formation and invasive growth, and perturbs multiple RTK signaling pathways.\",\n      \"method\": \"siRNA knockdown, ectopic expression, 3D invasion assays, tumorsphere formation, EMT marker analysis, in vivo xenograft growth\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain/loss-of-function with in vivo validation; single lab\",\n      \"pmids\": [\"26387542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRIG1 regulates the postnatal development of interstitial cells of Cajal (ICC-DMP and ICC-SMP) from LRIG1-positive smooth muscle progenitors; Lrig1-null mice lose KIT, anoctamin-1, and neurokinin 1 receptor staining in DMP and SMP regions and exhibit significant delays in small intestinal transit.\",\n      \"method\": \"Lineage tracing (Lrig1-CreERT2 × Rosa26-LSL-YFP), immunofluorescence, intestinal transit assays in Lrig1-null mice\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo lineage tracing combined with functional transit assays in knockout mice; single lab\",\n      \"pmids\": [\"25921371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The LRIG1 extracellular domain crystal structures were determined for the LRR domain and 3Ig domain at 2.3 Å resolution; the LRR domain and LRR-1Ig fragment are monomeric in solution while the 3Ig domain is dimeric; notably, no direct binding of isolated LRIG1 domains to soluble or cell-surface EGFR was detected by biosensor analysis, suggesting the full-length transmembrane context is required for receptor interaction.\",\n      \"method\": \"X-ray crystallography (2.3 Å), biosensor binding assays, baculovirus expression, analytical ultracentrifugation\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure determination combined with rigorous binding assays; important mechanistic constraint\",\n      \"pmids\": [\"25765764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRIG1 is an estrogen receptor α (ERα) target gene; estrogen stimulates LRIG1 accumulation, and disruption of estrogen induction enhances estrogen-dependent tumor cell growth; ErbB2 activation antagonizes ERα-driven LRIG1 expression; an LRIG1 mutant lacking the ErbB3 interaction motif cannot downregulate ErbB3, and LRIG1 loss in fulvestrant-treated cells permits ErbB3 upregulation and enhanced survival signaling.\",\n      \"method\": \"ChIP, ectopic expression, LRIG1 domain mutants, immunoblotting, ERα activation/inhibition experiments, cell growth assays\",\n      \"journal\": \"Oncogene / Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ERα-ChIP, domain mutant, and functional rescue across two independent studies\",\n      \"pmids\": [\"26148232\", \"21821674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Lrig1 physically interacts with TrkB and attenuates BDNF signaling; Lrig1 knockdown in hippocampal neurons enhances primary dendrite formation and proximal dendritic branching; Lrig1-deficient mice display morphological changes in proximal dendrite arborization and defects in social interaction; Lrig1 restricts BDNF-induced dendrite morphology in a cell-intrinsic manner.\",\n      \"method\": \"Co-immunoprecipitation (TrkB-Lrig1), siRNA knockdown, gain/loss-of-function in hippocampal neurons, Lrig1-/- mouse behavioral and morphological analysis\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP combined with in vivo KO mouse phenotype and gain/loss-of-function; single lab\",\n      \"pmids\": [\"26935556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A yeast two-hybrid screen and BioPlex data mining identified a LRIG1 protein interaction network including RAB4A, PON2, GAL3ST1, ZBTB16, LRIG2, CNPY3, HLA-DRA, GML, CNPY4, LRRC40, LRIG3, GLRX3, and PTPRK as functionally relevant LRIG1 interactors; PON2 co-localizes with LRIG1 and functionally promotes LRIG1-mediated PDGFRα downregulation.\",\n      \"method\": \"Yeast two-hybrid screen, shRNA functional evaluation in triple co-transfection system, BioPlex data mining, co-localization imaging\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — yeast two-hybrid with partial functional follow-up; single lab\",\n      \"pmids\": [\"29317492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Androgen receptor (AR) directly transactivates LRIG1 through binding to AR-binding sites in the LRIG1 locus; LRIG1 dampens ERBB expression in a cell-type-dependent manner; LRIG1 exhibits tumor-suppressive functions in both AR+ and AR- prostate cancer xenograft models and inhibits ERBB2-driven tumor growth; transgenic LRIG1 inhibits tumor development in Hi-Myc and TRAMP mouse models.\",\n      \"method\": \"ChIP (AR binding to LRIG1 locus), xenograft models, transgenic mouse models (Hi-Myc, TRAMP), siRNA/ectopic expression, ERBB signaling analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-validated direct AR transactivation combined with multiple in vivo genetic models\",\n      \"pmids\": [\"31792211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LRIG1 is a gatekeeper of neural stem cell (NSC) exit from quiescence; BMP-4 signaling induces a dormant quiescent NSC state while combined BMP-4/FGF-2 signaling induces a primed quiescent state with high LRIG1 and CD9; genetic disruption of Lrig1 in SVZ NSCs leads to enhanced proliferation; mechanistically, LRIG1 enables EGFR protein levels to increase while limiting EGFR signaling activation, priming cells for cell cycle re-entry.\",\n      \"method\": \"Single-cell analysis, in vitro quiescence induction (BMP-4/FGF-2), Lrig1 conditional knockout in SVZ, EGFR signaling assays, engraftment into adult SVZ\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of EGFR priming with in vivo genetic validation; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"33972529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LRIG proteins (LRIG1 and LRIG3 but not LRIG2) regulate BMP signaling; Lrig-null mouse embryonic fibroblasts are deficient in adipogenesis and BMP signaling, and this defect is rescued by LRIG1 or LRIG3 ectopic expression; C. elegans sma-10/LRIG mutants exhibit a lipid storage defect, demonstrating evolutionary conservation of LRIG function in BMP/lipid metabolism.\",\n      \"method\": \"Lrig-null MEF adipogenesis assays, BMP signaling assays, ectopic expression rescue, C. elegans genetic analysis\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cross-species genetic validation of BMP pathway role; single lab\",\n      \"pmids\": [\"33469151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Aberrant promoter CpG island methylation of LRIG1 is most prominent in basal/triple-negative breast cancer; global demethylation with 5-aza-2'-deoxycytidine restores LRIG1 expression; CRISPR/dCas9-mediated targeted TET1 demethylation and VP64 transcriptional activation at the LRIG1 CpG island increases LRIG1 expression and reduces cancer cell viability, demonstrating epigenetic silencing as a mechanism of LRIG1 repression.\",\n      \"method\": \"Methylation immunoprecipitation, 5-aza-2'-deoxycytidine treatment, CRISPR/dCas9-TET1 and dCas9-VP64 targeted demethylation/activation, qRT-PCR, immunoblotting\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — targeted epigenetic editing with functional consequence; single lab\",\n      \"pmids\": [\"35440669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LRIG1 is a VISTA (V-domain immunoglobulin suppressor of T cell activation) binding partner that acts as an inhibitory immune checkpoint receptor on CD8+ T cells; T cell-specific LRIG1 deletion in mice leads to expansion of tumor-specific cytotoxic T lymphocytes with increased effector function, superior antitumor responses, and reduced quiescent CTL populations; LRIG1 suppresses T cell receptor signaling pathways upon VISTA engagement.\",\n      \"method\": \"VISTA-LRIG1 binding assays, T cell-specific conditional knockout mice, tumor challenge models, CTL functional assays, flow cytometry of T cell subsets\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-ligand interaction combined with T cell-specific in vivo genetic model with defined signaling consequence\",\n      \"pmids\": [\"38758807\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LRIG1 is a transmembrane leucine-rich repeat/immunoglobulin-domain protein that functions as a pan-negative regulator of multiple receptor tyrosine kinases (ErbB1-4, Met, Ret, TrkB, PDGFRα) by physically associating with receptors via its extracellular domain, recruiting c-Cbl to promote receptor ubiquitination and lysosomal degradation (with Met degradation proceeding via a Cbl-independent, USP8-regulated ubiquitination of LRIG1 itself), and by shedding its ectodomain (via ADAM17) to act in a paracrine fashion; LRIG1 also functions as an inhibitory immune checkpoint receptor on T cells by engaging VISTA to suppress TCR signaling, is transcriptionally regulated by EGF (feedback induction), estrogen receptor α, and androgen receptor, and is epigenetically silenced by promoter methylation in some cancers, while its loss-of-function in vivo causes epidermal hyperplasia, intestinal adenomas with elevated ErbB signaling, impaired neural stem cell quiescence, and loss of interstitial cells of Cajal.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LRIG1 is a transmembrane leucine-rich repeat and immunoglobulin-domain protein that functions as a pan-negative regulator of receptor tyrosine kinase signaling and an emerging immune checkpoint receptor, governing stem cell quiescence, contact inhibition, and antitumor immunity across multiple tissues. LRIG1 physically associates with all four ErbB/EGFR family receptors, Met, Ret, and TrkB, recruiting the E3 ubiquitin ligase c-Cbl to promote receptor ubiquitylation and lysosomal degradation (with c-Cbl-independent destabilization of Met), thereby attenuating downstream MAPK, STAT3, and proliferative signaling; its own stability is controlled by the deubiquitinase USP8, and it forms a ternary complex with EGFR and E-cadherin to enforce contact inhibition [PMID:15282549, PMID:17178829, PMID:18171921, PMID:24828152, PMID:23208928]. Loss of Lrig1 in mouse epidermis, intestine, cornea, and brain causes stem/progenitor cell expansion, hyperproliferation, and tissue-specific pathology including duodenal adenomas, while in glioblastoma and breast cancer LRIG1 is epigenetically silenced by promoter CpG methylation and its re-expression suppresses tumor growth [PMID:22464327, PMID:19427292, PMID:24316976, PMID:35440669]. LRIG1 also engages the immune checkpoint ligand VISTA on T cells, and T cell-specific Lrig1 deletion expands tumor-specific cytotoxic T lymphocytes and enhances antitumor immunity [PMID:38758807].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"The initial cloning of LIG-1/LRIG1 established its domain architecture—extracellular leucine-rich repeats, immunoglobulin-like domains, a transmembrane segment, and cytoplasmic tail—but left its function unknown.\",\n      \"evidence\": \"cDNA cloning with sequence analysis and Northern blot/in situ hybridization in mouse brain\",\n      \"pmids\": [\"8798419\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional data; expression mapping limited to brain glial cells\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Knockout of Lrig1 in mice produced psoriasiform epidermal hyperplasia, providing the first evidence that LRIG1 is a negative regulator of epithelial proliferation, but the molecular target was unidentified.\",\n      \"evidence\": \"Gene-targeted KO mouse with histological and proliferative phenotyping\",\n      \"pmids\": [\"12067728\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target/pathway driving hyperproliferation unknown\", \"No receptor-level mechanism\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Two independent studies demonstrated that LRIG1 physically associates with all four ErbB receptors, recruits c-Cbl E3 ubiquitin ligase, and promotes receptor ubiquitylation and lysosomal degradation, establishing the core mechanism as feedback negative regulation of ErbB/EGFR signaling.\",\n      \"evidence\": \"Reciprocal co-immunoprecipitation, ubiquitylation assays, receptor half-life measurements, and NIH3T3 transformation assays in co-transfected cells\",\n      \"pmids\": [\"15282549\", \"15345710\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of LRIG1–EGFR interaction undefined\", \"Whether LRIG1 regulates non-ErbB RTKs unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Three advances extended LRIG1 biology: its LRR ectodomain alone binds EGFR at high affinity (Kd ~10 nM) and inhibits signaling; LRIG1 controls epidermal stem cell proliferation through EGFR; and LRIG1 negatively regulates Met via a c-Cbl-independent mechanism, establishing it as a pan-RTK regulator.\",\n      \"evidence\": \"Recombinant ectodomain binding assays, siRNA knockdown in keratinocytes with EGFR surface measurement, co-IP of LRIG1/Met with receptor half-life and invasion assays\",\n      \"pmids\": [\"16847455\", \"16877544\", \"17178829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural details of LRR–EGFR interface unresolved\", \"Mechanism of c-Cbl-independent Met destabilization unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"LRIG1 was shown to negatively regulate two additional RTKs—Ret (blocking GDNF binding and lipid raft recruitment) and constitutively active EGFRvIII in glioblastoma—broadening the spectrum of regulated receptors and demonstrating relevance in neuronal and cancer contexts.\",\n      \"evidence\": \"Co-IP, lipid raft fractionation, receptor autophosphorylation and trafficking assays, neurite outgrowth and glioblastoma functional assays\",\n      \"pmids\": [\"18171921\", \"18542056\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity determinants for different RTKs unclear\", \"No structural model of LRIG1–Ret interaction\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Lineage tracing in Lrig1-KO mice revealed that Lrig1 marks the junctional zone stem cell compartment of hair follicles and that its loss causes epidermal hyperproliferation and enhanced β-catenin-induced ectopic follicle formation, linking LRIG1 to stem cell identity and Wnt crosstalk.\",\n      \"evidence\": \"Lrig1-KO mouse, lineage tracing, skin reconstitution assays\",\n      \"pmids\": [\"19427292\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular link between LRIG1 and Wnt/β-catenin not resolved\", \"Relationship between ErbB regulation and follicle fate decisions unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Two independent studies showed Lrig1 restricts intestinal stem cell niche size by calibrating ErbB signaling amplitude; Lrig1 loss caused ErbB1-3 upregulation and duodenal adenomas, establishing LRIG1 as a tumor suppressor in the gut.\",\n      \"evidence\": \"Lrig1-KO mice with transcriptomics, ErbB expression analysis, lineage mapping, and genetic epistasis with Apc\",\n      \"pmids\": [\"22464327\", \"22388892\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LRIG1 tumor suppression is solely ErbB-dependent or involves additional pathways\", \"Human genetic validation in intestinal cancer lacking\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"LRIG1 was found to form a ternary complex with EGFR and E-cadherin to enforce contact inhibition, and separately to suppress EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling, revealing tissue-specific downstream effector mechanisms.\",\n      \"evidence\": \"Ternary complex co-IP, Lrig1-deletion airway hyperplasia model, inducible LRIG1 expression with gene expression profiling and ChIP in head/neck cancer\",\n      \"pmids\": [\"23208928\", \"23624915\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural basis of EGFR–LRIG1–E-cadherin complex unknown\", \"Whether E-cadherin involvement is tissue-restricted\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"LRIG1 was shown to inhibit STAT3-dependent inflammation to maintain corneal homeostasis; Lrig1 loss caused corneal blindness through a cell-fate switch rescued by STAT3 inhibition, revealing a signaling axis beyond canonical RTK regulation.\",\n      \"evidence\": \"Lrig1-KO and constitutively active STAT3 mouse models, pharmacological rescue, bone marrow chimeras\",\n      \"pmids\": [\"24316976\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LRIG1 directly modulates STAT3 or acts indirectly through upstream RTKs not distinguished\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of USP8 as a LRIG1-specific deubiquitinase revealed that LRIG1 stability is itself regulated by ubiquitin editing, and that disrupting the LRIG1–USP8 interaction triggers LRIG1 ubiquitylation, Hrs-mediated lysosomal trafficking, and co-degradation of LRIG1 with Met.\",\n      \"evidence\": \"Co-IP of LRIG1/USP8 and LRIG1/Hrs, ubiquitination and lysosomal trafficking assays upon anti-Met antibody treatment\",\n      \"pmids\": [\"24828152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitylation sites on LRIG1 not mapped\", \"Whether USP8 regulation of LRIG1 applies to all LRIG1–RTK complexes untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Crystal structure of the LRIG1 LRR and 3Ig domains at 2.3 Å revealed that the 3Ig domain dimerizes but, unexpectedly, purified LRIG1 ectodomains did not bind EGFR in solution, suggesting the interaction requires membrane context or additional factors.\",\n      \"evidence\": \"X-ray crystallography at 2.3 Å resolution, biosensor binding analysis with recombinant proteins\",\n      \"pmids\": [\"25765764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length LRIG1–EGFR complex structure unresolved\", \"Role of membrane anchoring or co-receptors in enabling interaction unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Multiple 2015 studies extended LRIG1 biology: domain mutagenesis identified the ErbB3-interaction motif required for ErbB3 downregulation; Lrig3 was shown to functionally oppose Lrig1 at ErbB receptors; LRIG1 depletion expanded stem cells and accelerated EMT; and Lrig1 was required for interstitial cell of Cajal development and intestinal transit.\",\n      \"evidence\": \"Domain deletion mutagenesis, Lrig1/Lrig3 co-expression assays, mammosphere and 3D invasion assays, Lrig1-null mouse lineage tracing with intestinal transit measurements\",\n      \"pmids\": [\"26148232\", \"23723069\", \"26387542\", \"25921371\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lrig1–Lrig3 opposition confirmed in only one lab\", \"Structural basis of LRIG1 domain selectivity for different ErbB receptors undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"LRIG1 was identified as a physical interactor and negative regulator of TrkB/NTRK2, restricting BDNF-induced dendritic branching in hippocampal neurons and influencing social behavior in mice, extending LRIG1 function to neurotrophin signaling.\",\n      \"evidence\": \"Co-IP of Lrig1/TrkB, shRNA and overexpression in hippocampal neurons, Lrig1-KO mouse behavioral assays\",\n      \"pmids\": [\"26935556\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LRIG1 promotes TrkB degradation via c-Cbl or a distinct mechanism not determined\", \"Broader neuropsychiatric relevance in humans unestablished\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Androgen receptor was shown to directly transactivate LRIG1 through ChIP-seq-identified binding sites, placing LRIG1 within the AR transcriptional program and explaining its tumor-suppressive role in prostate cancer where it dampens ERBB expression.\",\n      \"evidence\": \"ChIP-seq for AR binding at the LRIG1 locus, ectopic expression, Hi-Myc and TRAMP transgenic models, xenografts\",\n      \"pmids\": [\"31792211\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AR regulation of LRIG1 is direct in all prostate cancer subtypes\", \"Contribution of LRIG1 loss to castration resistance not assessed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"LRIG1 was demonstrated to regulate neural precursor cell proliferation in the developing neocortex through EGFR negative regulation, extending its stem cell gatekeeper role from adult tissues to embryonic brain development.\",\n      \"evidence\": \"Constitutive and conditional Lrig1-KO mice, co-IP of LRIG1/EGFR in cortical NSCs, BrdU/EdU proliferation assays\",\n      \"pmids\": [\"33053360\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cortical expansion from Lrig1 loss affects postnatal brain function untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A refined model showed LRIG1 gates NSC exit from quiescence by allowing EGFR protein accumulation while restraining signaling activation, distinguishing LRIG1's effect on receptor levels from its effect on signaling competence and explaining the primed quiescent state.\",\n      \"evidence\": \"In vitro quiescence model, conditional Lrig1 KO in SVZ, EGFR level vs. signaling dissection, single-cell analysis\",\n      \"pmids\": [\"33972529\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which LRIG1 uncouples EGFR accumulation from signaling activation not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"LRIG1 CpG island promoter methylation was causally linked to LRIG1 silencing in triple-negative breast cancer; CRISPR/dCas9-TET1 demethylation restored LRIG1 expression and reduced cancer cell viability, establishing epigenetic silencing as a tumor-relevant regulatory mechanism.\",\n      \"evidence\": \"Methylation immunoprecipitation, CRISPR/dCas9-TET1 and VP64 targeted epigenetic editing, cell viability assays\",\n      \"pmids\": [\"35440669\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether demethylation-mediated LRIG1 restoration is sufficient for tumor suppression in vivo\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"LRIG1 was discovered to function as an inhibitory immune checkpoint receptor engaging VISTA on T cells; T cell-specific Lrig1 deletion expanded tumor-specific CTLs and conferred sustained antitumor immunity, revealing a fundamentally new role outside RTK regulation.\",\n      \"evidence\": \"Co-IP of LRIG1/VISTA, T cell-specific conditional Lrig1 KO mouse, tumor challenge with flow cytometric immune profiling\",\n      \"pmids\": [\"38758807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of LRIG1–VISTA interaction undefined\", \"Whether LRIG1 checkpoint function is independent of its RTK-regulatory activity on T cells not resolved\", \"Therapeutic potential of anti-LRIG1 blockade not yet tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of LRIG1 engagement with EGFR and other RTKs in the membrane context (given that soluble ectodomains fail to interact), the mechanism by which LRIG1 uncouples receptor protein accumulation from signaling activation in stem cells, and whether the VISTA-binding immune checkpoint function and RTK-regulatory function of LRIG1 are mechanistically independent.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length LRIG1–RTK complex structure\", \"Mechanism of EGFR level vs. signaling uncoupling unknown\", \"Independence of immune checkpoint and RTK functions not tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 3, 4, 5, 6, 8, 9, 18, 29]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 13, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [28, 3, 27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 5, 6, 8, 9, 11, 18, 20, 21, 22, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 5, 6, 8, 9, 11, 18, 20, 21, 22, 25]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [25]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 16, 21]}\n    ],\n    \"complexes\": [\n      \"LRIG1–EGFR–E-cadherin ternary complex\"\n    ],\n    \"partners\": [\n      \"EGFR\",\n      \"ERBB2\",\n      \"ERBB3\",\n      \"ERBB4\",\n      \"MET\",\n      \"RET\",\n      \"NTRK2\",\n      \"VSIR\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"LRIG1 is a transmembrane negative-feedback regulator of receptor tyrosine kinase signaling that constrains stem cell proliferation, maintains epithelial homeostasis, and functions as an inhibitory immune checkpoint receptor. Its extracellular leucine-rich repeat and immunoglobulin-like domains physically associate with multiple RTKs—including all four ErbB family members, Met, Ret, and TrkB—and LRIG1 promotes their ubiquitination and degradation by recruiting c-Cbl (for EGFR) or through Cbl-independent, USP8-regulated ubiquitination of LRIG1 itself (for Met), while its ADAM17-shed ectodomain suppresses EGFR signaling in a paracrine fashion [PMID:15282549, PMID:17178829, PMID:21087604, PMID:24828152]. In vivo, LRIG1 loss causes epidermal hyperplasia, intestinal adenomas with elevated ErbB signaling, impaired neural stem cell quiescence, loss of interstitial cells of Cajal, and corneal degeneration driven by STAT3 hyperactivation [PMID:12067728, PMID:22464327, PMID:33972529, PMID:25921371, PMID:24316976]. LRIG1 also serves as a receptor for the inhibitory ligand VISTA on CD8+ T cells, where it suppresses TCR signaling and enforces cytotoxic T lymphocyte quiescence; T cell-specific LRIG1 deletion enhances antitumor immunity [PMID:38758807].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of LRIG1 (LIG-1) as a novel transmembrane glycoprotein with 15 LRRs and 3 Ig domains established its domain architecture and hinted at an adhesion/receptor function, but left its ligands and signaling role unknown.\",\n      \"evidence\": \"cDNA cloning, Northern blot, and in situ hybridization in mouse brain\",\n      \"pmids\": [\"8798419\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No ligand or binding partner identified\", \"Expression survey limited to brain\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Mapping human LRIG1 to chromosome 3p14.3—a region of frequent cancer deletion—raised the possibility of tumor-suppressive function but provided no mechanistic insight.\",\n      \"evidence\": \"cDNA cloning and chromosomal mapping of human LRIG1\",\n      \"pmids\": [\"11414704\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional data linking LRIG1 to tumor suppression\", \"No protein-level characterization\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Genetic ablation of Lrig1 in mice produced psoriasiform epidermal hyperplasia, demonstrating that LRIG1 is required to restrain keratinocyte proliferation in vivo and providing the first loss-of-function phenotype.\",\n      \"evidence\": \"Gene-targeted knockout mouse with histological analysis\",\n      \"pmids\": [\"12067728\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target of LRIG1 in epidermis not identified\", \"Signaling pathway not defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Discovery that LRIG1 physically associates with all four ErbB receptors, recruits c-Cbl to promote EGFR ubiquitination and degradation, and is itself transcriptionally induced by EGF established the core negative-feedback mechanism by which LRIG1 attenuates RTK signaling.\",\n      \"evidence\": \"Reciprocal Co-IP, ubiquitylation assays, receptor half-life measurements, and transformation assays in multiple cell types\",\n      \"pmids\": [\"15282549\", \"15345710\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether c-Cbl recruitment is the universal mechanism for all RTK targets was untested\", \"Structural basis of LRIG1–EGFR interaction unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Two advances broadened the LRIG1 model: the soluble LRR ectodomain was shown to bind EGFR with ~10 nM affinity and inhibit signaling extracellularly, while Lrig1 was identified as a Myc target marking junctional-zone epidermal stem cells capable of generating all epidermal lineages.\",\n      \"evidence\": \"Purified recombinant LRR domain binding/inhibition assays; single-cell profiling, skin reconstitution assays, and siRNA knockdown in keratinocytes\",\n      \"pmids\": [\"16847455\", \"16877544\", \"19427292\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Paracrine ectodomain shedding mechanism not yet characterized\", \"Whether LRIG1 marks stem cells in other epithelia was unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"LRIG1 was shown to negatively regulate Met receptor stability independently of c-Cbl, revealing that LRIG1 uses distinct degradation mechanisms for different RTK targets.\",\n      \"evidence\": \"Co-IP, receptor half-life assays, siRNA knockdown, and invasion assays in breast cancer cells\",\n      \"pmids\": [\"17178829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the ubiquitin ligase or sorting machinery for Cbl-independent Met degradation was unknown\", \"Whether Cbl-independence extends to other RTK targets untested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extension of the pan-RTK inhibitor model: LRIG1 physically interacts with Ret, blocks GDNF binding and lipid-raft recruitment, and suppresses neurite outgrowth; separately, LRIG1 negatively regulates the oncogenic EGFRvIII mutant via a Cbl-independent trafficking mechanism.\",\n      \"evidence\": \"Co-IP, lipid raft fractionation, phosphorylation and neurite outgrowth assays (Ret); trafficking assays and siRNA in glioblastoma cells (EGFRvIII)\",\n      \"pmids\": [\"18171921\", \"18542056\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural determinants of LRIG1 selectivity across different RTKs not defined\", \"In vivo validation of Ret regulation not provided\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstration that ADAM17 cleaves LRIG1 to release a soluble ectodomain that suppresses EGF signaling in neighboring cells in a paracrine fashion established a non-cell-autonomous mode of action.\",\n      \"evidence\": \"ADAM17 inhibitor (TAPI-2), ADAM17 overexpression, co-culture paracrine assays, tissue lysate immunoblotting\",\n      \"pmids\": [\"21087604\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cleavage site not mapped\", \"In vivo relevance of paracrine signaling not established genetically\", \"Mechanism of EGFR inhibition without receptor downregulation unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Lrig1 was established as a marker of quiescent intestinal stem cells and an in vivo tumor suppressor: Lrig1-null mice develop duodenal adenomas with elevated ErbB1-3, and Lrig1+ cells serve as the cell-of-origin for Apc-loss-driven adenomas, while separately LRIG3 was shown to functionally oppose LRIG1 by stabilizing ErbB receptors.\",\n      \"evidence\": \"Lineage tracing (Cre-lox), RNA-seq of Lrig1+ cells, Apc conditional deletion, intestinal organoid culture, receptor stability assays (LRIG3)\",\n      \"pmids\": [\"22464327\", \"22388892\", \"23723069\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LRIG1/LRIG3 opposition operates stoichiometrically or through distinct receptor pools unclear\", \"Mechanistic basis of LRIG1-mediated stem cell quiescence beyond ErbB inhibition not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"LRIG1 was linked to contact inhibition via a ternary complex with EGFR and E-cadherin, and independently shown to inhibit STAT3-dependent inflammation in the cornea; Lrig1-null corneas undergo a fate switch to keratinized epidermis rescued by STAT3 inhibition.\",\n      \"evidence\": \"Co-IP of ternary complex, Lrig1 KO airway and corneal phenotypes, STAT3 inhibitor rescue, bone marrow chimera experiments\",\n      \"pmids\": [\"23208928\", \"24316976\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT3 regulation is direct or downstream of RTK inhibition not fully resolved\", \"E-cadherin–LRIG1 interaction domain not mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of USP8 as a LRIG1-specific deubiquitinase and elucidation of Cbl-independent Met degradation via LRIG1 ubiquitination and Hrs-mediated lysosomal sorting provided the missing machinery for the Cbl-independent degradation pathway.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, lysosomal trafficking assays, USP8 siRNA knockdown\",\n      \"pmids\": [\"24828152\", \"23208509\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether USP8 regulates LRIG1 stability for all RTK targets not tested\", \"E3 ligase responsible for LRIG1 ubiquitination in the Cbl-independent pathway not identified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Crystal structures of the LRIG1 LRR and 3Ig domains revealed a monomeric LRR and dimeric 3Ig architecture, but no direct binding to soluble EGFR was detected, indicating that transmembrane context or coreceptors are required for receptor engagement; concurrently, LRIG1 was validated as a direct transcriptional target of ERα and AR, integrating hormonal regulation into the LRIG1 feedback circuit.\",\n      \"evidence\": \"X-ray crystallography at 2.3 Å, biosensor binding assays (EGFR); ChIP for ERα and AR binding, domain mutants, xenograft models\",\n      \"pmids\": [\"25765764\", \"26148232\", \"21821674\", \"31792211\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length LRIG1–EGFR complex structure not determined\", \"Whether membrane anchoring or a coreceptor mediates the interaction is unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Lineage tracing demonstrated that Lrig1+ smooth muscle progenitors give rise to interstitial cells of Cajal (ICC), and Lrig1-null mice lose ICC markers and exhibit delayed intestinal transit, expanding LRIG1's physiological roles beyond epithelial homeostasis.\",\n      \"evidence\": \"Lrig1-CreERT2 lineage tracing, immunofluorescence for ICC markers, intestinal transit assays in knockout mice\",\n      \"pmids\": [\"25921371\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RTK target responsible for ICC phenotype not identified\", \"Whether LRIG1 acts cell-autonomously in ICC progenitors not confirmed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"LRIG1 was shown to physically associate with TrkB and restrict BDNF-driven dendrite morphogenesis; Lrig1-null mice display altered proximal dendritic arborization and social interaction deficits, adding neurotrophic receptor regulation to the pan-RTK inhibitor model.\",\n      \"evidence\": \"Co-IP of TrkB–LRIG1, siRNA and Lrig1 KO in hippocampal neurons, behavioral analysis\",\n      \"pmids\": [\"26935556\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LRIG1 promotes TrkB degradation or only inhibits signaling not distinguished\", \"Neural circuit basis of behavioral phenotype not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"LRIG1 was identified as a gatekeeper of neural stem cell exit from quiescence: BMP-4/FGF-2 primes quiescent NSCs by upregulating LRIG1, which allows EGFR accumulation while constraining its signaling, poising cells for re-entry; separately, LRIG1 and LRIG3 were shown to positively regulate BMP signaling and adipogenesis.\",\n      \"evidence\": \"Single-cell analysis, conditional Lrig1 KO in SVZ NSCs, BMP-4/FGF-2 quiescence assays; Lrig-null MEF adipogenesis rescue, C. elegans sma-10 genetics\",\n      \"pmids\": [\"33972529\", \"33469151\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which LRIG1 allows EGFR accumulation without signaling is not molecularly resolved\", \"BMP receptor interaction with LRIG1 not demonstrated by direct binding\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Epigenetic silencing of LRIG1 via promoter CpG methylation was demonstrated in triple-negative breast cancer; CRISPR/dCas9-TET1 targeted demethylation restored LRIG1 expression and reduced cancer cell viability, providing a mechanistic explanation for LRIG1 loss in tumors lacking genetic deletion.\",\n      \"evidence\": \"Methylation immunoprecipitation, 5-aza-2′-deoxycytidine treatment, CRISPR/dCas9-TET1 and dCas9-VP64 epigenetic editing\",\n      \"pmids\": [\"35440669\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo tumor suppression by demethylation not tested\", \"Methylation status in other cancer types not systematically characterized in this study\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A fundamentally new function was uncovered: LRIG1 is a receptor for the inhibitory ligand VISTA on CD8+ T cells; T cell-specific LRIG1 deletion expands tumor-specific cytotoxic T lymphocytes and enhances antitumor immunity, establishing LRIG1 as an immune checkpoint receptor beyond its RTK-regulatory roles.\",\n      \"evidence\": \"VISTA–LRIG1 binding assays, T cell-specific conditional knockout mice, tumor challenge models, CTL functional assays, flow cytometry\",\n      \"pmids\": [\"38758807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of VISTA–LRIG1 interaction not determined\", \"Whether LRIG1 immune checkpoint function is independent of its RTK regulation not fully resolved\", \"Therapeutic potential of LRIG1 blockade not tested in combination immunotherapy\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A full-length LRIG1–RTK complex structure explaining how transmembrane context enables receptor engagement (absent in isolated ectodomain), the identity of the E3 ligase for Cbl-independent RTK degradation, and the interplay between LRIG1's RTK-regulatory and immune checkpoint functions remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length LRIG1–EGFR or LRIG1–VISTA co-structure\", \"E3 ligase for Cbl-independent pathway unknown\", \"Relative contribution of RTK inhibition vs. VISTA engagement to LRIG1 tumor suppression in vivo not dissected\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 5, 6, 8, 9, 10, 25, 28]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [31]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 6, 12]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5, 6, 8, 9, 10, 13, 14, 25, 28, 31]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 13, 14, 22]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [31]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 13, 27, 30]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"EGFR\",\n      \"ERBB2\",\n      \"ERBB3\",\n      \"ERBB4\",\n      \"MET\",\n      \"RET\",\n      \"NTRK2\",\n      \"USP8\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}